GSK plc 6-K, filed Feb 5, 2020
GSK plc (GSK)
6-K
2020-02-05
For: 2020-02-05
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on February 5, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February, 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
|
Issued:
Wednesday, 5 February 2020, London U.K.
|
|
GSK delivers 2019 sales of
£33.8 billion +10% AER, +8% CER (Pro-forma +4%
CER*)
Total
EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1%
CER
|
|
|
||
|
2019 financial and product highlights
|
||
|
●
|
Pharmaceuticals
£17.6 billion +2% AER, flat CER; Vaccines £7.2 billion
+21% AER, +19% CER; Consumer Healthcare £9 billion +17% AER,
+17% CER (Pro-forma +2% CER*)
|
|
|
●
|
Shingrix sales £1.8 billion +>100% AER, +>100%
CER driven by strong execution in the US
|
|
|
●
|
Total
Respiratory sales £3,081 million +18% AER, +15% CER.
Trelegy £518 million
+>100% AER, +>100% CER. Nucala £768 million +36% AER, +33%
CER
|
|
|
●
|
Total
HIV sales £4.9 billion, +3% AER +1% CER. Two-drug regimen
sales £422 million
|
|
|
●
|
Total
Group operating margin 20.6%. Adjusted Group operating margin 26.6%
reflecting increased R&D spending and impact of generic
Advair in the US partly
offset by improved Vaccines and Consumer Healthcare performance.
(Pharmaceuticals 26.2%; Vaccines 41.4%; Consumer Healthcare
20.8%)
|
|
|
●
|
Total
EPS 93.9p +27% AER; +23% CER primarily reflecting reduced
contingent consideration charges
|
|
|
●
|
Adjusted
EPS 123.9p +4% AER, +1% CER reflecting operating performance and
lower effective tax rate, partly offset by increased profit
allocation to non-controlling interests
|
|
|
●
|
Net
cash flow from operations £8.0 billion. Free cash flow
£5.1 billion
|
|
|
●
|
23p
dividend declared for the quarter, 80p for FY19
|
|
|
|
||
|
Pipeline highlights
|
||
|
●
|
Continued
strengthening of R&D pipeline in 2019: eight submissions, six
positive pivotal trial results and four new assets progressed into
pivotal trials
|
|
|
●
|
In 2020
expect at least six potential approvals in oncology, HIV, specialty
and respiratory
|
|
|
●
|
Expect
proof of concept readouts on several key pipeline assets including
four oncology medicines and vaccines for COPD and RSV
|
|
|
|
||
|
2020 guidance
|
||
|
●
|
Expect
Adjusted EPS to decline -1% to -4% CER
|
|
|
●
|
Expect
80p dividend for 2020
|
|
|
|
||
|
Preparing for two new companies
|
||
|
●
|
New
programme initiated to prepare for separation of GSK into two
companies: New GSK, a biopharma company with an R&D approach
focused on science related to the immune system, use of genetics
and new technologies; and a new leader in Consumer
Healthcare
|
|
|
●
|
As GSK
increases investment in R&D and new product launches, the
two-year separation programme aims to:
|
|
|
|
-
|
Drive a
common approach to R&D across modalities with improved capital
allocation
|
|
|
-
|
Align
and improve capabilities and efficiencies of global support
functions to support New GSK
|
|
|
-
|
Further
optimise supply chain and portfolio, including divestments of
non-core assets. Strategic review of prescription dermatology
underway
|
|
|
-
|
Prepare
Consumer Healthcare to operate as a standalone company
|
|
●
|
Programme
to target delivery of £0.7 billion of annual savings by 2022
with total costs estimated at £2.4 billion (of which £1.6
billion cash). Programme expected to deliver improved operating
performance, with meaningful improvements from 2022. Anticipated
divestment proceeds largely expected to cover programme cash
costs
|
|
|
●
|
Additional
one-time costs to prepare Consumer Healthcare for separation
estimated at £600-700 million
|
|
|
|
||
|
|
|||||||||||
|
2019 results
|
2019
|
|
Growth
|
|
Q4 2019
|
|
Growth
|
||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
33,754
|
|
10
|
|
8
|
|
8,899
|
|
9
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
6,961
|
|
27
|
|
23
|
|
1,902
|
|
22
|
|
29
|
|
Total
earnings per share
|
93.9p
|
|
27
|
|
23
|
|
26.2p
|
|
6
|
|
12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
8,972
|
|
3
|
|
-
|
|
1,852
|
|
(16)
|
|
(11)
|
|
Adjusted
earnings per share
|
123.9p
|
|
4
|
|
1
|
|
24.8p
|
|
(21)
|
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
cash from operating activities
|
8,020
|
|
(5)
|
|
|
|
3,453
|
|
(16)
|
|
|
|
Free
cash flow
|
5,073
|
|
(11)
|
|
|
|
2,599
|
|
(22)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Total results are presented under ‘Financial
performance’ on pages 11 and 26 and Adjusted results
reconciliations are presented on pages 21, 22, 35 and 36. Adjusted
results are a non-IFRS measure that may be considered in addition
to, but not as a substitute for, or superior to, information
presented in accordance with IFRS. Adjusted results are defined on
page 9 and £% or AER% growth, CER% growth, free cash flow and
other non-IFRS measures are defined on page 60. GSK provides
guidance on an Adjusted results basis only, for the reasons set out
on page 10. All expectations, guidance and targets regarding future
performance and dividend payments should be read together with
“Outlook, assumptions and cautionary statements” on
pages 61 and 62.
|
|
|
*
|
Reported
AER and CER growth rates include five months’ results of
former Pfizer consumer healthcare business. Pro-forma CER growth
rates are calculated as if the equivalent five months of Pfizer
consumer healthcare business results, as reported by Pfizer, were
included in the comparative period of 2018. See “Pro-forma
growth” on page 10.
|
|
Emma Walmsley, Chief Executive Officer, GSK said:
“GSK
delivered a good performance in 2019 with growth in sales and
earnings, together with strong cash generation. We also made
excellent progress in all three of our long-term priorities:
Innovation, Performance and Trust, strengthening our pipeline,
improving operational execution and reshaping the
company.
“In
2020, our first priority remains Innovation, to progress our
pipeline and support new product launches. Recent data readouts
underpin our decision to further increase investment in R&D and
these new products. At the same time, we are again focused on
operational execution, including delivering a successful
integration in Consumer Healthcare, and we are also preparing for
the future, starting a new two-year programme to get GSK ready for
separation.
“All
of this aims to support future growth, deliver significant value
creation, and set up two new leading companies in biopharma and
consumer healthcare, each with the opportunity to improve the
health of hundreds of millions of people.”
|
|
2020 guidance
|
|
We set
out below earnings guidance for 2020. This reflects our
expectations for growth in key new products, and the start of a
two-year period in which we will continue to increase investment in
these products and in our R&D pipeline, alongside
implementation of our new programme which will prepare the Group
for separation.
In 2020
we expect Adjusted EPS to decline in the range of -1% to -4% at
CER. This guidance excludes any impact in 2020 from any further
material divestments beyond those previously announced and any
potential impact on our business from the Coronavirus
outbreak.
All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with “Outlook,
assumptions and cautionary statements” on pages 61 and
62.
If
exchange rates were to hold at the closing rates on 31 January 2020
($1.31/£1, €1.19/£1 and Yen 143/£1) for the
rest of 2020, the estimated negative impact on 2020 Sterling
turnover growth would be around 3% and if exchange gains or losses
were recognised at the same level as in 2019, the estimated
negative impact on 2020 Sterling Adjusted EPS growth would be
around 5%.
|
|
Results presentation
|
|
A
webcast of the quarterly results presentation hosted by Emma
Walmsley, GSK CEO, will be held at 2pm GMT on 5 February 2020.
Presentation materials will be published on www.gsk.com prior to the webcast and a
transcript of the webcast will be published
subsequently.
Information
available on GSK’s website does not form part of, and is not
incorporated by reference into, this Results
Announcement.
|
|
Operating performance – 2019
|
|
Turnover
|
|
|
2019
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
|
|
17,554
|
|
2
|
|
-
|
|
Vaccines
|
|
|
7,157
|
|
21
|
|
19
|
|
Consumer
Healthcare
|
|
|
8,995
|
|
17
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,706
|
|
9
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Corporate
and other unallocated turnover
|
|
|
48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group
turnover
|
|
|
33,754
|
|
10
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Pro-forma
growth
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
Group
turnover for the year increased 10% AER, 8% CER to £33,754
million, with growth delivered by Vaccines and Consumer Healthcare
and Pharmaceuticals flat at CER. Pro-forma turnover growth for the
Group was 4% CER.
Pharmaceuticals
turnover in the year was £17,554 million, up 2% AER, but flat
at CER. HIV sales were up 3% AER, 1% CER, to £4,854 million,
with growth in Juluca and
Dovato partly offset by
declines in Triumeq and
Tivicay. Respiratory sales
were up 18% AER, 15% CER, to £3,081 million, on growth of
Trelegy Ellipta and
Nucala. Sales of
Established Pharmaceuticals were £8,776 million, down 7% AER,
8% CER, including the impact of loss of exclusivity of Advair.
Vaccines turnover grew 21% AER, 19% CER to £7,157 million,
primarily driven by growth in sales of Shingrix. Meningitis vaccines also contributed
significantly to growth.
Consumer
Healthcare sales grew 17% AER, 17% CER to £8,995 million. On a
pro-forma basis, sales grew 2%, driven by strong performance in the
Oral health category, partly offset by
a decline in Skin health.
|
|
Operating profit
Total operating profit for the year was £6,961 million
compared with £5,483 million in 2018. Adjusted operating
profit was £8,972 million, up 3% AER, but flat at CER on a
turnover increase of 8% CER. The Adjusted operating margin of 26.6%
was down 1.8 percentage points at AER, 2.1 percentage points at CER
and down 1.9 percentage points CER on a pro-forma
basis. Reduced re-measurement charges
on the contingent consideration liabilities and an increase in
value of the shares in Hindustan Unilever Limited to be received on
the disposal of Horlicks and other brands were partly offset by increased
charges for Major restructuring, primarily arising from write-downs
in manufacturing sites.
The
reduction in pro-forma Adjusted operating profit primarily
reflected continuing price pressure, particularly in Respiratory,
investment in R&D including a significant increase in Oncology
and investments in promotional product support. This was partly
offset by the benefit from sales growth, particularly Vaccines, a
more favourable mix in Vaccines and Consumer Healthcare, favourable
inventory adjustments in Vaccines and continued tight control of
ongoing costs across all three businesses.
Earnings per share
Total
earnings per share for the year was 93.9p, compared with 73.7p in
2018. Adjusted EPS of 123.9p compared with 119.4p in 2018, up 4%
AER, 1% CER, with Adjusted operating profit flat at CER. The
improvement primarily resulted from a reduced effective tax rate
and an increased share of after tax profits of associates as a
result of a non-recurring income tax benefit in Innoviva, partly
offset by increased net finance costs and a higher non-controlling
interest allocation of Consumer Healthcare profits.
Cash flow
Net cash inflow from operating activities was £8,020 million
(2018: £8,421 million) and free cash flow was £5,073
million (2018: £5,692 million). The reduction primarily
reflected the adverse timing of payments for returns and rebates,
the initial step-down impact from US Advair generic competition, increased capital expenditure
and higher payments for restructuring and significant legal
matters.
|
|
Operating performance – Q4 2019
|
|
Turnover
|
|
|
Q4 2019
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
|
|
4,558
|
|
(5)
|
|
(4)
|
|
Vaccines
|
|
|
1,742
|
|
18
|
|
21
|
|
Consumer
Healthcare
|
|
|
2,571
|
|
35
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,871
|
|
8
|
|
10
|
|
|
|
|
|
|
|
|
|
|
Corporate
and other unallocated turnover
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group
turnover
|
|
|
8,899
|
|
9
|
|
11
|
|
|
|
|
|
|
|
|
|
|
Pro-forma
growth
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Operating profit
Total
operating profit was £1,902 million in Q4 2019 compared with
£1,554 million in Q4 2018. Adjusted operating profit was
£1,852 million, 16% lower than Q4 2018 at AER and 11% lower at
CER on a turnover increase of 11% CER. The Adjusted operating
margin of 20.8% was down 6.0 percentage points at AER, 5.2
percentage points at CER and down 4.8 percentage points CER on a
pro-forma basis.
Re-measurement credits on the contingent consideration liabilities,
increased profit on disposals and reduced restructuring costs were
partly offset by the unwind of the fair value uplift on inventory
arising on completion of the Consumer Healthcare Joint Venture with
Pfizer and a decrease in the value of the shares in Hindustan
Unilever Limited. GSK expects the transaction to complete around
the end of Q1 2020, subject to legal and regulatory approvals.
Operating profit was also impacted by increased investment in
R&D, investments in promotional product support, and continuing
price pressure, together with a non-restructuring related
write-down in a manufacturing site. This was partly offset by the
benefit from sales growth, particularly in Vaccines, a more
favourable mix in Vaccines and continued tight control of ongoing
costs across all three businesses.
Earnings per share
Total
earnings per share was 26.2p, compared with 24.7p in Q4 2018.
Adjusted EPS of 24.8p compared with 31.2p in Q4 2018, down 21% AER,
16% CER, on an 11% CER decrease in Adjusted operating profit. This
reflected an increased non-controlling interest allocation of
Consumer Healthcare profits and increased net finance costs, partly
offset by a reduced effective tax rate.
Cash flow
Net cash inflow from operating activities was £3,453 million
(Q4 2018: £4,119 million) and free cash flow was £2,599
million (Q4 2018: £3,317 million). The reduced free cash flow
primarily reflected the adverse timing of payments for returns and
rebates, the step-down impact from US Advair generic competition, higher significant legal
payments and lower operating profits.
|
|
R&D pipeline
|
|
39 medicines in development, 15 Vaccines
|
|
Pipeline news flow highlights since Q3 2019:
|
|
Oncology
|
|
Zejula
(niraparib, PARP inhibitor)
|
|
|
●
|
A
regulatory application was submitted to the US FDA for the use of
Zejula in ovarian cancer as
first-line maintenance based on the results of the PRIMA
study.
|
|
●
|
Data
from the OPAL study assessing the safety and efficacy of new
treatment combinations in patients with recurrent, platinum
resistant ovarian cancer are in-house and analysis is
ongoing.
|
|
Belantamab mafodotin (GSK2857916, BCMA
immunoconjugate)
|
|
|
●
|
Pivotal
data from the DREAMM-2 study of belantamab mafodotin in
relapsed/refractory multiple myeloma patients were published in The
Lancet Oncology demonstrating a clinically meaningful overall
response rate.
|
|
●
|
The US
FDA granted priority review of belantamab mafodotin for patients
with relapsed/refractory multiple myeloma. Approval is expected in
H1 2020.
|
|
●
|
The
European Medicines Agency’s (EMA) Committee for Human
Medicinal Products accepted for accelerated assessment the
marketing authorisation application for belantamab mafodotin for
the treatment of patients with relapsed or refractory multiple
myeloma.
|
|
●
|
The
first patient was dosed in the DREAMM-9 pivotal study of belantamab
mafodotin in combination for the first-line treatment of multiple
myeloma.
|
|
Dostarlimab (TSR-042, PD-1 antagonist)
|
|
|
●
|
A
regulatory application was submitted to the US FDA for second line
treatment of patients with endometrial cancer based on the results
of the GARNET study.
|
|
GSK3359609 (ICOS agonist)
|
|
|
●
|
The
first patient was dosed in the phase II/III INDUCE-3 study of
GSK’609 in combination with pembrolizumab in first-line
recurrent/metastatic head and neck squamous cell carcinoma
(HNSCC).
|
|
GSK3326595 (PRMT5 inhibitor)
|
|
|
●
|
Proof
of concept was achieved for GSK’595 in adenoid cystic
carcinoma (ACyC). Data from additional cohorts in 2020 will inform
next steps.
|
|
GSK2636771 (PI3kb inhibitor)
|
|
|
●
|
GSK’771
for cancer was terminated as part of ongoing portfolio
prioritisation.
|
|
HIV/Infectious diseases
|
|
Tivicay
(dolutegravir)
|
|
|
●
|
Regulatory
applications were submitted to the US FDA and EMA for the
first-ever dispersible formulation of dolutegravir (DTG) for
children with HIV.
|
|
Cabotegravir + rilpivirine
|
|
|
●
|
A
complete response letter was received from the US FDA for the use
of investigational cabotegravir and rilpivirine long-acting regimen
for treatment of HIV-1 infection in virologically supressed
adults.
|
|
Fostemsavir (attachment inhibitor)
|
|
|
●
|
Regulatory
applications were submitted to the US FDA and the EMA for
fostemsavir, an investigational, first-in-class attachment
inhibitor for heavily treatment-experienced adults with multi-drug
resistant HIV-1 infection who are unable to form a suppressive
regimen.
|
|
GSK3810109 (broadly neutralising antibody)
|
|
|
●
|
An
exclusive licensing agreement was announced with the US National
Institutes of Health for the investigational broadly neutralising
antibody (bNAb) N6LS, with potential for long-acting HIV treatment
and prevention.
|
|
Immuno-inflammation
|
|
Benlysta
(belimumab)
|
|
|
●
|
Positive
phase III headline results were reported from the BLISS-LN study of
Benlysta in patients with
lupus nephritis. Regulatory submission is expected in H1
2020.
|
|
●
|
Preliminary
data from a small proof of mechanism study with belimumab +
rituximab for Sjogren’s syndrome are in-house. Additional
data are needed and the study is ongoing.
|
|
GSK3358699 (targeted BET inhibitor)
|
|
|
●
|
GSK’699
for rheumatoid arthritis was moved back to research.
|
|
Respiratory
|
|
Trelegy
(FF/UMEC/VI)
|
|
|
●
|
Trelegy received regulatory approval for COPD in
China.
|
|
Nucala
(mepolizumab)
|
|
|
●
|
Positive
data from the pivotal study of Nucala in the treatment of patients
with Hypereosinophilic Syndrome (HES) demonstrated a reduction in
flares for this rare disease. Regulatory submission is expected in
2020.
|
|
●
|
The
first patient was dosed in the pivotal MATINEE study of
Nucala in patients with
COPD characterised by frequent exacerbations and eosinophil
level.
|
|
Other pharmaceuticals
|
|
Daprodustat
|
|
|
●
|
Futility
analysis has been performed on phase III cardiovascular outcome
studies which are continuing without modification.
|
|
Vaccines
|
|
Shingrix
|
|
|
●
|
A file
was submitted in the EU to achieve a broadened indication aiming at
covering immunocompromised populations.
|
|
Bexsero
|
|
|
●
|
Two
independent meningitis B studies published in the New England Journal of Medicine
demonstrated the real-world impact of Bexsero in reducing disease in infants
and underscored the need for individual protection among
adolescents.
|
|
Menveo
|
|
|
●
|
The US
FDA approved the indication of a single booster dose administration
of Menveo to individuals
aged 15 to 55 years who are at continued risk of meningococcal
disease if at least four years have elapsed since a previous
dose.
|
|
RSV maternal
|
|
|
●
|
RSV
maternal progressed to phase II with the start of the first time in
human trial in pregnant women.
|
|
Tuberculosis vaccine
|
|
|
●
|
Our
phase II tuberculosis vaccine candidate was licensed to the Bill
& Melinda Gates Medical Research Institute for continued
development.
|
|
HIV vaccine
|
|
|
●
|
Data
from the HVTN 702 study of our HIV vaccine candidate for the
developing world did not meet the required success criteria.
Further development of this vaccine candidate has been
discontinued.
|
|
Contents
|
Page
|
|
|
|
|
Total
and Adjusted results
|
9
|
|
Financial
performance – 2019
|
11
|
|
Financial
performance – three months ended 31 December
2019
|
26
|
|
Cash
generation
|
39
|
|
Returns
to shareholders
|
40
|
|
|
|
|
Income
statements
|
42
|
|
Statement
of comprehensive income – year ended 31 December
2019
|
43
|
|
Statement
of comprehensive income – three months ended 31 December
2019
|
44
|
|
Pharmaceuticals
turnover – year ended 31 December 2019
|
45
|
|
Pharmaceuticals
turnover – three months ended 31 December 2019
|
46
|
|
Vaccines
turnover – year ended 31 December 2019
|
47
|
|
Vaccines
turnover – three months ended 31 December 2019
|
48
|
|
Balance
sheet
|
49
|
|
Statement
of changes in equity
|
50
|
|
Cash
flow statement – year ended 31 December 2019
|
51
|
|
Segment
information
|
52
|
|
Legal
matters
|
54
|
|
Additional
information
|
55
|
|
Reconciliation
of cash flow to movements in net debt
|
59
|
|
Net
debt analysis
|
59
|
|
Free
cash flow reconciliation
|
59
|
|
Reporting
definitions
|
60
|
|
Outlook,
assumptions and cautionary statements
|
61
|
|
Contacts
|
|
GSK –
one of the world’s leading research-based pharmaceutical and
healthcare companies – is committed to improving the quality
of human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
|
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Mary
Hinks-Edwards
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Kristen
Neese
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
Total and Adjusted results
|
|
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined below and pro-forma growth and other
non-IFRS measures are defined on page 60.
GSK
believes that Adjusted results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Adjusted
results exclude the following items from Total results, together
with the tax effects of all of these items:
|
|
●
|
amortisation
of intangible assets (excluding computer software)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
Major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant legal charges (net of insurance recoveries) and
expenses on the settlement of litigation and government
investigations; other operating income other than royalty income,
and other items
|
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses are retained within both Total and Adjusted
results.
As
Adjusted results include the benefits of Major restructuring
programmes but exclude significant costs (such as significant
legal, major restructuring and transaction items) they should not
be regarded as a complete picture of the Group’s financial
performance, which is presented in Total results. The exclusion of
other Adjusting items may result in Adjusted earnings being
materially higher or lower than Total earnings. In particular, when
significant impairments, restructuring charges and legal costs are
excluded, Adjusted earnings will be higher than Total
earnings.
GSK is
undertaking a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy, or following material acquisitions. Costs, both
cash and non-cash, of these programmes are provided for as
individual elements are approved and meet the accounting
recognition criteria. As a result, charges may be incurred over a
number of years following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Adjusted results, providing further information
on the key Adjusting items, are set out on pages 21, 22, 35 and
36.
GSK
provides earnings guidance to the investor community on the basis
of Adjusted results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
Pro-forma growth
The
acquisition of the Pfizer consumer healthcare business completed on
31 July 2019 and so GSK’s reported results include five
months of results of the former Pfizer consumer healthcare business
from 1 August 2019.
The
Group has presented pro-forma growth rates at CER for turnover,
Adjusted operating profit and operating profit by business taking
account of this transaction. Pro-forma growth rates for the quarter
are calculated comparing reported results for Q4 2019, calculated
applying the exchange rates used in the comparative period, with
the results for Q4 2018 adjusted to include the equivalent three
months of results of the former Pfizer consumer healthcare business
during Q4 2018, as consolidated (in US$) and included in
Pfizer’s US GAAP results. Similarly, pro-forma growth rates
at CER for 2019 are calculated comparing reported results for 2019,
calculated applying the exchange rates used in the comparative
period, with the results for 2018, adjusted to include the
equivalent five months of results of the former Pfizer consumer
healthcare business, as consolidated (in US$) and included in
Pfizer’s US GAAP results.
|
|
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of
dolutegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 85% of the Total
earnings and 82% of the Adjusted earnings of ViiV Healthcare for
2019.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, principally
dolutegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent re-measurements are
reflected within other operating income/expense and within
Adjusting items in the income statement in each period. At 31
December 2019, the liability, which is discounted at 8.5%, stood at
£5,103 million, on a post-tax basis.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance of the relevant products in the previous quarter. These
payments reduce the balance sheet liability and hence are not
recorded in the income statement. The cash payments made to
Shionogi by ViiV Healthcare in 2019 were £865
million.
Because
the liability is required to be recorded at the fair value of
estimated future payments, there is a significant timing difference
between the charges that are recorded in the Total income statement
to reflect movements in the fair value of the liability and the
actual cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 41 and 42 of the Annual Report
2018.
|
|
Financial performance – 2019
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
2019
£m
|
|
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
33,754
|
|
30,821
|
|
10
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(11,863)
|
|
(10,241)
|
|
16
|
|
16
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
21,891
|
|
20,580
|
|
6
|
|
4
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(11,402)
|
|
(9,915)
|
|
15
|
|
13
|
|
Research
and development
|
(4,568)
|
|
(3,893)
|
|
17
|
|
15
|
|
Royalty income
|
351
|
|
299
|
|
17
|
|
17
|
|
Other
operating income/(expense)
|
689
|
|
(1,588)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
6,961
|
|
5,483
|
|
27
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
98
|
|
81
|
|
|
|
|
|
Finance
expense
|
(912)
|
|
(798)
|
|
|
|
|
|
Profit
on disposal of associates
|
-
|
|
3
|
|
|
|
|
|
Share
of after tax profits of
associates
and joint ventures
|
74
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
6,221
|
|
4,800
|
|
30
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(953)
|
|
(754)
|
|
|
|
|
|
Tax rate %
|
15.3%
|
|
15.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
5,268
|
|
4,046
|
|
30
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
623
|
|
423
|
|
|
|
|
|
Profit
attributable to shareholders
|
4,645
|
|
3,623
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,268
|
|
4,046
|
|
30
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
93.9p
|
|
73.7p
|
|
27
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
The
Adjusted results for the Group are set out below. Reconciliations
between Total results and Adjusted results for 2019 and 2018 are
set out on pages 21 and 22.
|
|
|
2019
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Reported
growth
CER%
|
|
Pro-forma
growth
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
33,754
|
|
100
|
|
10
|
|
8
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(10,079)
|
|
(29.9)
|
|
10
|
|
10
|
|
5
|
|
Selling,
general and
administration
|
(10,715)
|
|
(31.7)
|
|
13
|
|
12
|
|
7
|
|
Research
and development
|
(4,339)
|
|
(12.9)
|
|
16
|
|
14
|
|
13
|
|
Royalty
income
|
351
|
|
1.1
|
|
17
|
|
17
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
8,972
|
|
26.6
|
|
3
|
|
-
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
8,236
|
|
|
|
2
|
|
(1)
|
|
|
|
Adjusted
profit after tax
|
6,918
|
|
|
|
6
|
|
3
|
|
|
|
Adjusted
profit attributable to
shareholders
|
6,131
|
|
|
|
4
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
123.9p
|
|
|
|
4
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit by business
|
2019
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Reported
growth
CER%
|
|
Pro-forma
growth
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
7,964
|
|
45.4
|
|
(5)
|
|
(8)
|
|
(8)
|
|
Pharmaceuticals
R&D*
|
(3,369)
|
|
|
|
26
|
|
23
|
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Pharmaceuticals
|
4,595
|
|
26.2
|
|
(20)
|
|
(22)
|
|
(22)
|
|
Vaccines
|
2,966
|
|
41.4
|
|
53
|
|
46
|
|
46
|
|
Consumer
Healthcare
|
1,874
|
|
20.8
|
|
24
|
|
22
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,435
|
|
28.0
|
|
3
|
|
-
|
|
(3)
|
|
Corporate
& other unallocated
costs
|
(463)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
8,972
|
|
26.6
|
|
3
|
|
-
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
Operating
profit of Pharmaceuticals R&D segment, which is the
responsibility of the Chief Scientific Officer and President,
R&D. It excludes ViiV Healthcare R&D expenditure, which is
reported within the Pharmaceuticals segment.
|
|
Turnover
|
|
Pharmaceuticals turnover
|
|
|
2019
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Respiratory
|
3,081
|
|
18
|
|
15
|
|
HIV
|
4,854
|
|
3
|
|
1
|
|
Immuno-inflammation
|
613
|
|
30
|
|
25
|
|
Oncology
|
230
|
|
-
|
|
-
|
|
Established
Pharmaceuticals
|
8,776
|
|
(7)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
17,554
|
|
2
|
|
-
|
|
|
|
|
|
|
|
|
US
|
7,402
|
|
(1)
|
|
(4)
|
|
Europe
|
4,125
|
|
1
|
|
2
|
|
International
|
6,027
|
|
5
|
|
4
|
|
|
|
|
|
|
|
|
|
17,554
|
|
2
|
|
-
|
|
|
|
|
|
|
|
|
Pharmaceuticals
turnover in the year was £17,554 million, up 2% AER, but flat
at CER. HIV sales were up 3% AER, 1% CER, to £4,854 million,
with growth in Juluca and
Dovato partly offset by
declines in Triumeq and
Tivicay. Respiratory sales
were up 18% AER, 15% CER, to £3,081 million, on growth of
Trelegy Ellipta and
Nucala. Sales of
Established Pharmaceuticals were £8,776 million, down 7% AER,
8% CER, including the impact of loss of exclusivity of Advair.
In the
US, sales declined 1% AER, 4% CER. Continued growth of Nucala, Trelegy Ellipta and Benlysta was more than offset by the
decline in Established Products including the loss of exclusivity
of Advair. Excluding
Advair and Relvar/Breo Ellipta, which were
impacted by genericisation of the ICS/LABA market, growth was 13%
AER, 9% CER. In Europe, sales grew 1% AER, 2% CER, with strong
growth in Respiratory partly offset by a decline in Established
Pharmaceuticals. International grew 5% AER, 4% CER, with growth in
all therapy areas.
Respiratory
Total
Respiratory sales were up 18% AER, 15% CER, with strong growth in
all regions. Ellipta
product sales grew 13% AER, 10% CER, with Europe up 26% AER, 27%
CER and International up 29% AER, 27% CER on Trelegy and Relvar/Breo growth. Nucala was up 36% AER, 37% CER in
Europe and 56% AER, 50% CER in International. In the US,
Trelegy Ellipta and Nucala growth offset the decline in
Relvar/Breo Ellipta on post generic ICS/LABA price
pressure.
Sales
of Nucala were £768
million in the year and grew 36% AER, 33% CER, with US sales of
£453 million up 33% AER, 28% CER, including the impact of the
new at-home use application.
Sales
of Ellipta products were up
13% AER, 10% CER to £2,313 million driven by growth in Europe
and International regions. In the US, sales grew 4% AER, but were
flat at CER, reflecting continued competitive pricing pressures for
ICS/LABAs, post generic Advair. In Europe, sales grew 26% AER,
27% CER, and in International by 29% AER, 27% CER. Sales of
Trelegy Ellipta contributed
£518 million globally in the year, driven by an increase in US
market share.
Relvar/Breo Ellipta sales were down 11% AER, 13% CER, driven
by the US, where Relvar/Breo Ellipta declined 34% AER, 37% CER as a
result of competitive pricing pressures and the impact of generic
Advair on the US ICS/LABA
market. In Europe and International, Relvar/Breo Ellipta continued to grow, up 11% AER,
12% CER in Europe, and 21% AER, 19% CER in
International.
HIV
HIV
sales grew 3% AER, 1% CER to £4,854 million in the year. The
dolutegravir franchise grew 5% AER, 2% CER, delivering sales of
£4,633 million. The remaining portfolio, £221 million and
5% of total HIV sales, declined 27% AER, 27% CER and reduced the
overall HIV growth by two percentage points at AER and one
percentage point at CER.
Sales
of dolutegravir products were £4,633 million, with
Triumeq and Tivicay delivering sales of £2,549
million and £1,662 million, respectively. The two-drug
regimens, Juluca and
Dovato, delivered sales of
£422 million in the year with combined growth more than
offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to
the new portfolio.
In the
US, following the launch of Dovato in April 2019, combined sales of
the two-drug regimens were £350 million. Total dolutegravir
sales grew 4% AER but were flat at CER, reflecting a year-on-year
share decline as the business transitions to the new two-drug
portfolio, offset by a net price benefit. In Europe, total
dolutegravir sales were flat at AER and flat at CER, with strong
growth in market share offsetting price erosion and higher clawback
payments. Dovato and
Juluca reported combined
sales of £65 million. International grew strongly with total
dolutegravir sales growth of 22% AER, 22% CER, driven by
Tivicay and Triumeq.
Oncology
Sales
of Zejula, were £229
million in the period from the date of acquisition, comprising
£134 million in the US and £95 million in
Europe.
Immuno-inflammation
Sales
of Benlysta in the year
were up 30% AER, 25% CER to £613 million, including sales of
the sub-cutaneous formulation of £268 million. In the US,
Benlysta grew 27% AER, 23%
CER to £535 million.
Established
Pharmaceuticals
Sales
of Established Pharmaceuticals in the year were £8,776
million, down 7% AER, 8% CER.
Established
Respiratory products declined 10% AER, 11% CER to £3,900
million, with the decline in Advair/Seretide partly offset by higher
sales of Ventolin, Flovent
and allergy
products. In the US, a
generic version of Advair
was launched in February, resulting in a 54% AER, 56% CER decline
in the year. In Europe, Seretide sales were down 16% AER, 16%
CER to £502 million, reflecting continued competition from
generic products and the transition of the Respiratory portfolio to
newer products. In International, sales of Seretide were flat at AER but down 1%
CER. Globally, Ventolin
grew by 27% AER, 25% CER, driven by the strong uptake of an
authorised generic version in the US.
The
remainder of the Established Pharmaceuticals portfolio declined 5%
AER, 6% CER to £4,876 million, including Lamictal down 8% AER, 10% CER to
£566 million on generic competition and lower sales of
Viread in International.
These declines were partly offset by Augmentin, up 6% AER, 6% CER to
£602 million in the year, driven by strong growth in
International.
|
|
Vaccines turnover
|
|
|
2019
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Meningitis
|
1,018
|
|
16
|
|
15
|
|
Influenza
|
541
|
|
3
|
|
1
|
|
Shingles
|
1,810
|
|
>100
|
|
>100
|
|
Established
Vaccines
|
3,788
|
|
2
|
|
1
|
|
|
|
|
|
|
|
|
|
7,157
|
|
21
|
|
19
|
|
|
|
|
|
|
|
|
US
|
3,905
|
|
45
|
|
39
|
|
Europe
|
1,488
|
|
(5)
|
|
(4)
|
|
International
|
1,764
|
|
8
|
|
9
|
|
|
|
|
|
|
|
|
|
7,157
|
|
21
|
|
19
|
|
|
|
|
|
|
|
|
Vaccines turnover grew 21% AER, 19% CER to £7,157 million,
primarily driven by growth in sales of Shingrix.
Meningitis vaccines also contributed to growth mainly due to
Bexsero
demand and share gains in
the US together with stronger demand in International. Established
Vaccines grew 2% AER, 1% CER to £3,788 million, primarily
reflecting strong growth in Boostrix,
Hepatitis,
Synflorix and
Infanrix/Pediarix,
partly offset by lower Cervarix
sales in International and
supply constraints in MMRV vaccines.
Meningitis
Meningitis
sales grew 16% AER, 15% CER to £1,018 million. Bexsero sales grew 16% AER, 16% CER to
£679 million, driven by demand and share gains in the US
together with stronger demand in International and Europe, partly
offset by the completion of the vaccination of catch-up cohorts in
certain markets in Europe. Menveo grew 15% AER, 13% CER, primarily
reflecting improved supply and higher demand in
International.
Influenza
Fluarix/FluLaval sales were up 3% AER, 1% CER to £541
million, reflecting strong sales execution in the US, partly offset
by increased price competition in the US and lower demand in
Europe.
Shingles
Shingrix recorded sales of £1,810 million, primarily
driven by continued strong uptake and the favourable benefit of
prior-period rebate adjustments in the US. Germany and Canada also
contributed to growth.
Established
Vaccines
Sales
of DTPa-containing vaccines (Infanrix, Pediarix and Boostrix) grew 10% AER, 8% CER.
Infanrix/Pediarix sales
grew 8% AER, 6% CER to £733 million, reflecting favourable
year-on-year US CDC stockpile movements and stronger demand in
International, partly offset by competitive pressures in Europe.
Boostrix sales were up 13%
AER, 11% CER to £584 million mainly due to strong demand in
International together with share gains and higher demand in the
US.
Hepatitis vaccines grew 8% AER, 6% CER to £874 million,
primarily due to favourable year-on-year CDC stockpile movements
and the continued benefit from a competitor supply shortage in the
US, partly offset by supply constraints and lower demand in
Europe.
Synflorix sales grew 10% AER, 11% CER to £468 million,
primarily due to stronger demand in International.
Rotarix sales were up 7% AER, 6% CER to £558 million,
reflecting stronger demand in International and the US together
with favourable phasing in International.
MMRV
vaccines sales declined 24% AER, 23% CER to £232 million,
largely driven by supply constraints in Europe and
International.
Cervarix sales were down 64% AER, 64% CER to £50
million, reflecting lower demand and expected returns due to
competitive pressure in China, together with lower demand elsewhere
in International.
|
|
Consumer Healthcare turnover
|
|
|
|
|
2019
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Wellness
|
|
|
4,526
|
|
15
|
|
14
|
|
Oral
health
|
|
|
2,673
|
|
7
|
|
7
|
|
Nutrition
|
|
|
1,176
|
|
83
|
|
81
|
|
Skin
health
|
|
|
620
|
|
7
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,995
|
|
17
|
|
17
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
2,583
|
|
41
|
|
36
|
|
Europe
|
|
|
2,456
|
|
5
|
|
6
|
|
International
|
|
|
3,956
|
|
13
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,995
|
|
17
|
|
17
|
|
|
|
|
|
|
|
|
|
|
Pro-forma
growth
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Consumer
Healthcare sales grew 17% AER, 17% CER in 2019 to £8,995
million. On a pro-forma basis, sales grew 2%, driven by strong
performance in the Oral health
category, partly offset by a decline in Skin health. At a regional
level, growth was driven by the US and International following the
acquisition of the Pfizer portfolio, while on a pro-forma basis
growth was driven primarily by the International region with strong
performance in India and China.
Divestments and the phasing out of low margin contract
manufacturing had a negative impact on pro-forma growth of
approximately one percentage point.
Sales
of the Consumer Healthcare business included five months of Pfizer
brand sales arising after the creation of the Joint Venture. The
Pfizer brands have been included in the existing categories and
geographic regions used to report Consumer Healthcare
sales. GSK expects to revise this
category structure for reporting from Q1 2020
onwards.
Wellness
Wellness
sales grew 15% AER, 14% CER to £4,526 million for the year. On a
pro-forma basis, sales were flat, with growth in Pain relief offset
by a decline in Respiratory and the phasing out of low margin
contract manufacturing. Pain relief benefited from continued
strong performance of
Panadol
and Advil with the latter reflecting ongoing recovery from
now resolved supply issues. Voltaren saw weaker performance and was
also impacted by retail stock movements. Respiratory sales declined as growth in
Flonase was more than
offset by weaker performance in Theraflu, following a strong cold and
flu comparator in 2018. Growth was also impacted by a decline in
other Respiratory brands.
Oral
health
Oral
health sales grew 7% AER, 7% CER to £2,673 million. Sensodyne saw double-digit, broad-based
growth, with strong performance in the US and India benefiting from
new product innovations. Gum
health grew in double digits with broad-based growth, while
Denture care grew in mid-single digits. Oral health growth was also
impacted by a decline in sales of non-strategic
brands.
Nutrition
Nutrition
sales grew 83% AER, 81% CER to £1,176 million, largely due to
the inclusion of the Pfizer vitamins, minerals and supplements
portfolio. On a pro-forma basis, sales were flat, reflecting the strong performance of
Horlicks,
offset by declines in other Nutrition products due to the alignment
of in-market inventory levels of some Pfizer brands. Growth was
also impacted by the divestment of Horlicks and Maxinutrition in the UK.
Skin
health
Skin
health sales grew 7% AER, 7% CER to £620 million, largely due to the
addition of Chapstick from
the Pfizer portfolio. On a pro-forma basis, sales declined in
mid-single digits, largely due to divestments of small tail brands
in the US and UK.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 35.1%, 1.9 percentage
points higher at AER and 2.4 percentage points higher in CER terms
compared with 2018. This reflected an increase in the costs of
Major restructuring programmes, primarily as a result of write
downs in a number of manufacturing sites, the unwind of the fair
market value uplift on inventory arising on completion of the
Consumer Healthcare Joint Venture with Pfizer and increased
amortisation of intangible assets.
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 29.9%, 0.1 percentage points higher at
AER and 0.5 percentage points higher at CER compared with 2018. On
a pro-forma basis, Adjusted cost of sales as a percentage of
turnover was 29.9%, 0.3 percentage points higher at CER, than in
2018. This reflected continued adverse pricing pressure in
Pharmaceuticals, particularly in Respiratory, an unfavourable
product mix in Pharmaceuticals and a number of non-restructuring
related write downs in manufacturing sites. This was partly offset
by a more favourable product mix in Vaccines, primarily due to
growth of Shingrix in the
US, a favourable impact of inventory adjustments in Vaccines and a
further contribution from integration and restructuring savings in
Pharmaceuticals and Consumer Healthcare.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 33.8%, 1.6
percentage points higher at AER and 1.6 percentage points higher at
CER compared with 2018. This included increased significant legal
charges arising from the settlement of existing matters and
provisions for ongoing litigation, costs related to the acquisition
of the Pfizer consumer healthcare business and a reversal of an
indemnity receivable from Novartis following a tax settlement, with
an equivalent release of a tax provision which was reflected in the
tax charge, as well as increased restructuring costs.
Excluding
these and other Adjusting items, Adjusted SG&A costs as a
percentage of turnover were 31.7%, 1.0 percentage point higher at
AER than in 2018 and 1.0 percentage point higher on a CER basis. On
a pro-forma basis, Adjusted SG&A costs as a percentage of
turnover was 31.7%, 0.8 percentage points higher at CER, compared
with 2018.
The
growth in Adjusted SG&A costs of 13% AER, 12% CER and 7% CER on
a pro-forma basis reflected increased investment resulting from the
acquisition of Tesaro and in promotional product support,
particularly for new launches in Vaccines, Respiratory and HIV as
well as increased costs for a number of legal settlements. This was
partly offset by the continuing benefit of restructuring in
Pharmaceuticals and the tight control of ongoing costs,
particularly in non-promotional spending across all three
businesses.
Research and development
Total
R&D expenditure was £4,568 million (13.5% of turnover), up
17% AER, 15% CER. Adjusted R&D expenditure was £4,339
million (12.9% of turnover), 16% higher at AER, 14% higher at CER
than in 2018. On a pro-forma basis, Adjusted R&D expenditure
grew 13% CER compared with 2018.
Pharmaceuticals
R&D expenditure was £3,348 million, up 19% AER, 16% CER,
with a significant increase in study and clinical trial material
investment in Oncology compared with 2018 reflecting the
progression of assets from the Tesaro acquisition, primarily
Zejula and dostarlimab, and
a number of other programmes, including belantamab mafodotin,
NY-ESO, ICOS and bintrafusp alfa, as well as increased spending on
the progression of key non-Oncology assets, such as aGM-CSF for
rheumatoid arthritis. This was partly offset by savings from the
early phase portfolio reprioritisation in late 2018. R&D
expenditure in Vaccines and Consumer Healthcare was £718
million and £273 million, respectively.
Royalty income
Royalty
income was £351 million (2018: £299 million), up 17% AER,
17% CER, primarily reflecting increased royalties on sales of
Gardasil.
|
|
Other operating income/(expense)
Net
other operating income of £689 million (2018: £1,588
million expense) primarily reflected the profit on disposal of
rabies and tick-borne encephalitis vaccines (£306 million) and
a number of other asset disposals together with an increase in
value of the shares in Hindustan Unilever Limited to be received on
the disposal of Horlicks
and other Consumer Healthcare brands. The cumulative increase in
value since the signing of the proposed transaction was £240
million.
Other
income also included accounting credits of £127 million (2018:
£1,846 million expense) arising from the re-measurement of the
contingent consideration liabilities related to the acquisitions of
the former Shionogi-ViiV Healthcare joint venture and the former
Novartis Vaccines business and the liabilities for the Pfizer put
option and Pfizer and Shionogi preferential dividends in ViiV
Healthcare. This included a re-measurement charge of £31
million (2018: £1,188 million) for the contingent
consideration liability due to Shionogi, primarily arising from the
unwind of the discounting, partly offset by changes in exchange
rate assumptions and sales forecasts. 2018 also included a
re-measurement charge of £658 million in relation to the
Consumer Healthcare put option.
|
|
Operating profit
Total
operating profit was £6,961 million in 2019 compared with
£5,483 million in 2018. Reduced re-measurement charges on the
contingent consideration liabilities, no Consumer Healthcare put
option charge, increased profits on disposals and an increase in
value of the shares in Hindustan Unilever Limited to be received on
the disposal of Horlicks
and other Consumer Healthcare brands were partly offset by
increased charges for Major restructuring, primarily arising from
write downs in a number of manufacturing sites and costs to
integrate the Consumer Healthcare Joint Venture, and increased
significant legal charges.
Excluding
these and other Adjusting items, Adjusted operating profit was
£8,972 million, 3% higher than 2018 at AER but flat at CER on
a turnover increase of 8% CER. The Adjusted operating margin of
26.6% was 1.8 percentage points lower at AER, and 2.1 percentage
points lower on a CER basis than in 2018. On a pro-forma basis,
Adjusted operating profit was 3% lower at CER on a turnover
increase of 4% CER. The Adjusted pro-forma operating margin of
26.6% was 1.9 percentage points lower on a CER basis than in
2018.
The
reduction in pro-forma Adjusted operating profit primarily
reflected continuing price pressure, particularly in Respiratory,
including the impact of the launch of a generic version of
Advair in the US in
February 2019, investment in R&D including a significant
increase in Oncology investment, partly on the assets from the
Tesaro acquisition, and investments in promotional product support,
particularly for new launches in Vaccines, HIV and Respiratory.
This was partly offset by the benefit from sales growth,
particularly in Vaccines, a more favourable mix in Vaccines and
Consumer Healthcare, favourable inventory adjustments in Vaccines
and the continued benefit of restructuring with tight control of
ongoing costs across all three businesses.
Contingent
consideration cash payments which are made to Shionogi and other
companies reduce the balance sheet liability and hence are not
recorded in the income statement. Total contingent consideration
cash payments in 2019 amounted to £893 million (2018:
£1,137 million). This included cash payments made to Shionogi
of £865 million (2018: £793 million).
Operating profit by business
Pharmaceuticals
operating profit was £4,595 million, down 20% AER, 22% CER
with turnover flat at CER. The operating margin of 26.2% was 7.1
percentage points lower at AER than in 2018 and 7.2 percentage
points lower on a CER basis. This primarily reflected the increase
in cost of sales percentage due to the continued impact of lower
prices, particularly in Respiratory, including the impact of the
launch of a generic version of Advair in the US in February 2019, an
unfavourable product mix, primarily as a result of the decline in
Advair and growth in lower
margin products, a significant increase in Oncology R&D and
investment in new product support and targeted priority markets,
together with a number of non-restructuring related write downs in
manufacturing sites and higher legal costs. This was partly offset
by the continued benefit of restructuring and tight control of
ongoing costs and the benefits of re-prioritisation of the R&D
portfolio.
Vaccines operating profit was £2,966 million, 53% AER, 46% CER
higher than in 2018 on a turnover increase of 19% CER. The
operating margin of 41.4% was 8.5 percentage points higher at AER
than in 2018 and 7.3 percentage points higher on a CER basis. This
was primarily driven by enhanced operating leverage from strong
sales growth, particularly Shingrix in the US, improved product mix and higher royalty
income. Increased SG&A investment to support business growth
was partly offset by income from one-off
settlements.
Consumer
Healthcare operating profit was £1,874 million, up 24% AER,
22% CER higher on a turnover increase of 17% CER. On a pro-forma
basis, operating profit was £1,874 million, 4% CER higher on a
turnover increase of 2% CER. The operating margin of 20.8% was 1.0
percentage point higher at AER and 0.9 percentage points higher on
a CER basis than in 2018. The pro-forma operating margin of 20.8%
was 0.5 percentage points higher on a CER basis. This primarily
reflected continued manufacturing restructuring savings, improved
growth from higher margin power brands and the divestment of lower
margin tail products, as well as tight control of other operating
expenses, partly offset by increased investment in
promotion.
Net finance costs
Total
net finance costs were £814 million compared with £717
million in 2018. Adjusted net finance costs were £810 million
compared with £698 million in 2018. The increase primarily
reflected higher debt levels following the acquisition from
Novartis of its stake in the Consumer Healthcare Joint Venture in
June 2018 and the acquisition of Tesaro in January 2019, as well as
an adverse comparison with a one-off accounting adjustment of
£20 million to amortisation of interest charges in 2018. This
was partly offset by the benefit from older bonds being refinanced
at lower interest rates, a fair value gain on interest rate swaps
and interest of £23 million in Q3 2018 on an historic tax
settlement. Following the introduction of IFRS 16,
‘Leases’, finance costs included an unwind of the
discount on the lease liability of £39 million in the
year.
Share of after tax profits of associates and joint
ventures
The
share of after tax profits of associates was £74 million
(2018: £31 million). This included a one-off adjustment of
£51 million to reflect GSK’s share of increased after
tax profits of Innoviva primarily as a result of a non-recurring
income tax benefit.
Taxation
The
charge of £953 million represented an effective tax rate on
Total results of 15.3% (2018: 15.7%) and reflected the different
tax effects of the various Adjusting items. Tax on Adjusted profit
amounted to £1,318 million and represented an effective
Adjusted tax rate of 16.0% (2018: 19.0%), reflecting the impact of
the settlement of a number of open issues with tax
authorities.
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2018. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods which are open and not yet
agreed by tax authorities. The ultimate liability for such matters
may vary from the amounts provided and is dependent upon the
outcome of agreements with relevant tax authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £623 million (2018: £423 million). The increase was
primarily due to an increased allocation of ViiV Healthcare profits
of £482 million (2018: £251 million) and higher net
profits in some of the Group’s other entities with
non-controlling interests. This was partly offset by the lower
allocation of Consumer Healthcare profits of £70 million
(2018: £117 million) following the buyout of Novartis’
interest in June 2018 and the completion of the new Consumer
Healthcare Joint Venture with Pfizer on 31 July 2019, and which
included the unwind of the fair value uplift on acquired
inventory.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £787 million (2018: £674 million). The
increase in allocation reflected an increased allocation of
Consumer Healthcare profits of £204 million (2018: £118
million), an increased allocation of ViiV Healthcare profits of
£512 million (2018: £501 million) and higher net profits
in some of the Group’s other entities with non-controlling
interests.
Earnings per share
Total
earnings per share was 93.9p, compared with 73.7p in 2018. The
increase in earnings per share primarily reflected reduced
re-measurement charges on the contingent consideration liabilities
and put options, an increase in the value of the shares in
Hindustan Unilever Limited to be received on the disposal of
Horlicks and other Consumer
Healthcare brands, a reduced effective tax rate and the increased
share of after tax profit of the associate Innoviva.
Adjusted
EPS of 123.9p compared with 119.4p in 2018, up 4% AER, 1% CER, with
Adjusted operating profit flat at CER. The improvement primarily
resulted from a reduced effective tax rate and an increased share
of after tax profits of associates as a result of a non-recurring
income tax benefit in Innoviva, partly offset by increased net
finance costs and a higher non-controlling interest allocation of
Consumer Healthcare profits.
Currency impact on 2019 results
The
results for 2019 are based on average exchange rates, principally
£1/$1.28, £1/€1.14 and £1/Yen 139. Comparative
exchange rates are given on page 56. The period-end exchange rates
were £1/$1.32, £1/€1.18 and £1/Yen
143.
In
2019, turnover increased 10% AER, 8% CER. Total EPS was 93.9p
compared with 73.7p in 2018. Adjusted EPS was 123.9p compared with
119.4p in 2018, up 4% AER, 1% CER. The positive currency impact
primarily reflected the weakness of Sterling, particularly against
the US$ and Yen, partly offset by weakness in emerging market
currencies, relative to 2018. Exchange gains or losses on the
settlement of intercompany transactions had a negligible impact on
the positive currency impact of three percentage points on Adjusted
EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for 2019
and 2018 are set out below.
|
|
Year ended 31 December 2019
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
33,754
|
|
|
|
|
|
33,754
|
|
Cost of sales
|
(11,863)
|
713
|
30
|
658
|
383
|
-
|
(10,079)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
21,891
|
713
|
30
|
658
|
383
|
-
|
23,675
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(11,402)
|
|
4
|
332
|
104
|
247
|
(10,715)
|
|
Research and development
|
(4,568)
|
64
|
49
|
114
|
|
2
|
(4,339)
|
|
Royalty income
|
351
|
|
|
|
|
|
351
|
|
Other operating income/(expense)
|
689
|
|
|
1
|
(142)
|
(548)
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
6,961
|
777
|
83
|
1,105
|
345
|
(299)
|
8,972
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(814)
|
|
|
5
|
|
(1)
|
(810)
|
|
Share of after tax profits of
associates and joint ventures
|
74
|
|
|
|
|
|
74
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
6,221
|
777
|
83
|
1,110
|
345
|
(300)
|
8,236
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(953)
|
(156)
|
(17)
|
(208)
|
(124)
|
140
|
(1,318)
|
|
Tax rate %
|
15.3%
|
|
|
|
|
|
16.0%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
5,268
|
621
|
66
|
902
|
221
|
(160)
|
6,918
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
623
|
|
|
|
164
|
|
787
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
4,645
|
621
|
66
|
902
|
57
|
(160)
|
6,131
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
93.9p
|
12.6p
|
1.3p
|
18.2p
|
1.2p
|
(3.3)p
|
123.9p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of
shares (millions)
|
4,947
|
|
|
|
|
|
4,947
|
|
|
––––––––––––
|
|
|
|
|
|
––––––––––––
|
|
Year ended 31 December 2018
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
30,821
|
|
|
|
|
|
30,821
|
|
Cost of sales
|
(10,241)
|
536
|
69
|
443
|
15
|
|
(9,178)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
20,580
|
536
|
69
|
443
|
15
|
|
21,643
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(9,915)
|
|
2
|
315
|
98
|
38
|
(9,462)
|
|
Research and development
|
(3,893)
|
44
|
45
|
49
|
|
20
|
(3,735)
|
|
Royalty income
|
299
|
|
|
|
|
|
299
|
|
Other operating (expense)/income
|
(1,588)
|
|
|
2
|
1,864
|
(278)
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
5,483
|
580
|
116
|
809
|
1,977
|
(220)
|
8,745
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(717)
|
|
|
4
|
(3)
|
18
|
(698)
|
|
Profit on disposal of associates
|
3
|
|
|
|
|
(3)
|
-
|
|
Share of after tax profits of
associates and joint ventures
|
31
|
|
|
|
|
|
31
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
4,800
|
580
|
116
|
813
|
1,974
|
(205)
|
8,078
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(754)
|
(109)
|
(19)
|
(170)
|
(239)
|
(244)
|
(1,535)
|
|
Tax rate %
|
15.7%
|
|
|
|
|
|
19.0%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
4,046
|
471
|
97
|
643
|
1,735
|
(449)
|
6,543
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
423
|
|
|
|
251
|
|
674
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
3,623
|
471
|
97
|
643
|
1,484
|
(449)
|
5,869
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
73.7p
|
9.6p
|
2.0p
|
13.1p
|
30.2p
|
(9.2)p
|
119.4p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of
shares (millions)
|
4,914
|
|
|
|
|
|
4,914
|
|
|
––––––––––––
|
|
|
|
|
|
––––––––––––
|
|
Major restructuring and integration
Within
the Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete.
|
|
Total
Major restructuring charges incurred in 2019 were £1,105
million (2018: £809 million), analysed as
follows:
|
|
|
2019
|
|
2018
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018
major restructuring
programme
(incl. Tesaro)
|
227
|
|
572
|
|
799
|
|
279
|
|
90
|
|
369
|
|
Consumer
Healthcare Joint
Venture
integration
programme
|
248
|
|
4
|
|
252
|
|
-
|
|
-
|
|
-
|
|
Combined
restructuring and
integration
programme
|
10
|
|
44
|
|
54
|
|
330
|
|
110
|
|
440
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
485
|
|
620
|
|
1,105
|
|
609
|
|
200
|
|
809
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges primarily arose from restructuring of the manufacturing
organisation, R&D and some administrative functions as well as
the integration of Tesaro under the 2018 major restructuring
programme and integration costs under the Consumer Healthcare Joint
Venture integration programme. Non-cash charges under the 2018
major restructuring programme primarily related to announced plans
to restructure the manufacturing network.
Total
cash payments made in 2019 were £645 million, £316
million for the existing Combined restructuring and integration
programme (2018: £528 million) and £164 million (2018:
£9 million) under the 2018 major restructuring programme
including the settlement of certain charges accrued in previous
quarters and a further £165 million relating to the Consumer
Healthcare Joint Venture integration programme.
The
analysis of Major restructuring charges by business was as
follows:
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
Pharmaceuticals
|
651
|
|
563
|
|
Vaccines
|
58
|
|
104
|
|
Consumer
Healthcare
|
321
|
|
72
|
|
|
|
|
|
|
|
1,030
|
|
739
|
|
Corporate
& central functions
|
75
|
|
70
|
|
|
|
|
|
|
Total
Major restructuring costs
|
1,105
|
|
809
|
|
|
|
|
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
Cost of
sales
|
658
|
|
443
|
|
Selling,
general and administration
|
332
|
|
315
|
|
Research
and development
|
114
|
|
49
|
|
Other
operating expense
|
1
|
|
2
|
|
|
|
|
|
|
Total
Major restructuring costs
|
1,105
|
|
809
|
|
|
|
|
|
|
The Combined restructuring and integration programme delivered
incremental annual cost savings in the year of £0.3 billion.
The 2018 major restructuring programme delivered incremental cost
savings in the year of £0.2 billion.
Total cash charges for the Combined restructuring and integration
programme are now expected to be approximately £4.0 billion
with non-cash charges of £1.4 billion. The total of £5.4
billion represents a reduction of £0.3 billion from the
originally approved £5.7 billion. The programme has now
delivered approximately £4.2 billion of annual savings,
including an estimated currency benefit of £0.2 billion. The
programme is expected to deliver by the end of 2020 total annual
savings of £4.3 billion on a constant currency basis,
including an estimated benefit of £0.2 billion from currency
on the basis of 2019 average exchange rates. The programme is
substantially complete and therefore GSK will cease external
reporting of total costs and benefits of the Combined restructuring
and integration programme from 2020 onwards.
The
Group acquired Tesaro in January 2019, and is expected to incur
around £50 million of integration and restructuring cash
costs, leading to annual cost-saving benefits of around £50
million. This has been added to and reported as part of the
existing 2018 major restructuring programme.
The
2018 major restructuring programme, now including Tesaro, is
expected to cost £1.75 billion over the period to 2021, with
cash costs of £0.85 billion and non-cash costs of £0.9
billion, and is expected to deliver annual savings of around
£450 million by 2021 (at 2019 rates). These savings are
intended to be fully re-invested to help fund targeted increases in
R&D and commercial support of new products.
The
completion of the new Consumer Healthcare Joint Venture with Pfizer
is expected to realise substantial cost synergies, generating total
annual cost savings of £0.5 billion by 2022 for expected cash
costs of £0.7 billion and non-cash charges of £0.3
billion, plus additional capital expenditure of £0.2 billion.
Up to 25% of the cost savings are intended to be reinvested in the
business to support innovation and other growth
opportunities.
The
Group has initiated a two-year Separation Preparation programme to
prepare for the separation of GSK into two companies: New GSK, a
biopharma company with an R&D approach focused on science
related to the immune system, the use of genetics and new
technologies, and a new leader in Consumer Healthcare. The
programme aims to:
|
|
●
|
Drive a
common approach to R&D with improved capital
allocation
|
|
●
|
Align
and improve the capabilities and efficiency of global support
functions to support New GSK
|
|
●
|
Further
optimise the supply chain and product portfolio, including the
divestment of non-core assets. A strategic review of prescription
dermatology is underway
|
|
●
|
Prepare
Consumer Healthcare to operate as a standalone company
|
|
The
programme will target delivery of £0.7 billion of annual
savings by 2022 and £0.8 billion by 2023, with total costs
estimated at £2.4 billion, of which £1.6 billion is
expected to be cash costs. The proceeds of anticipated divestments
are largely expected to cover the cash costs of the
programme.
Additional
one-time costs to prepare Consumer Healthcare for separation are
estimated at £600-700 million, excluding transaction
costs.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £345 million (2018:
£1,977 million). This included a net £127 million
accounting credit for the re-measurement of the contingent
consideration liabilities related to the acquisitions of the former
Shionogi-ViiV Healthcare joint venture and the former Novartis
Vaccines business and the liabilities for the Pfizer put option and
Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
Charge/(credit)
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
Consumer
Healthcare Joint Venture put option
|
-
|
|
658
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including
Shionogi preferential dividends)
|
31
|
|
1,188
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(234)
|
|
(58)
|
|
Contingent
consideration on former Novartis Vaccines business
|
76
|
|
58
|
|
Release
of fair value uplift on acquired Pfizer inventory
|
366
|
|
-
|
|
Other
adjustments
|
106
|
|
131
|
|
|
|
|
|
|
Total
transaction-related charges
|
345
|
|
1,977
|
|
|
|
|
|
|
The
£31 million charge relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented
an increase in the valuation of the contingent consideration due to
Shionogi, primarily as a result of a £435 million unwind of
the discount, partly offset by updated exchange rate assumptions
and adjustments to sales forecasts. The £234 million credit
relating to the ViiV Healthcare put options and Pfizer preferential
dividends represented a reduction in the valuation of the put
option as a result of adjustments to multiples and sales forecasts
as well as updated exchange rate assumptions.
Other
adjustments included transaction costs arising on completion of the
Consumer Healthcare Joint Venture with Pfizer and a reversal of an
indemnity receivable from Novartis following a tax settlement, with
an equivalent release of a tax provision.
An
explanation of the accounting for the non-controlling interests in
ViiV Healthcare is set out on page 10.
Divestments, significant legal charges and other items
Divestments
and other items included a profit on disposal of rabies and
tick-borne encephalitis vaccines (£306 million), a gain in the
year of £143 million arising from the increase in value of the
shares in Hindustan Unilever Limited to be received on the disposal
of Horlicks and other
Consumer Healthcare brands, as well as equity investment
impairments and certain other Adjusting items together with the
profit on a number of asset disposals. A charge of £251
million (2018: £33 million) for significant legal matters
included the settlement of existing matters as well as provisions
for ongoing litigation. Significant legal cash payments were
£294 million (2018: £39 million).
|
|
Financial performance – Q4 2019
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,899
|
|
8,197
|
|
9
|
|
11
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(3,248)
|
|
(2,904)
|
|
12
|
|
14
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
5,651
|
|
5,293
|
|
7
|
|
9
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(3,443)
|
|
(2,620)
|
|
31
|
|
31
|
|
Research
and development
|
(1,243)
|
|
(1,076)
|
|
16
|
|
17
|
|
Royalty income
|
82
|
|
79
|
|
4
|
|
4
|
|
Other
operating income/(expense)
|
855
|
|
(122)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
1,902
|
|
1,554
|
|
22
|
|
29
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
11
|
|
24
|
|
|
|
|
|
Finance
expense
|
(206)
|
|
(209)
|
|
|
|
|
|
Share
of after tax profits of associates
and
joint ventures
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,711
|
|
1,374
|
|
25
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(194)
|
|
(74)
|
|
|
|
|
|
Tax rate %
|
11.3%
|
|
5.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,517
|
|
1,300
|
|
17
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
218
|
|
85
|
|
|
|
|
|
Profit
attributable to shareholders
|
1,299
|
|
1,215
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,517
|
|
1,300
|
|
17
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
26.2p
|
|
24.7p
|
|
6
|
|
12
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
The
Adjusted results for the Group are set out below. Reconciliations
between Total results and Adjusted results for Q4 2019 and Q4 2018
are set out on pages 35 and 36.
|
|
|
Q4 2019
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Reported
growth
CER%
|
|
Pro-forma
growth
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
8,899
|
|
100
|
|
9
|
|
11
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(2,848)
|
|
(32.0)
|
|
12
|
|
15
|
|
4
|
|
Selling,
general and
administration
|
(3,117)
|
|
(35.0)
|
|
23
|
|
23
|
|
11
|
|
Research
and development
|
(1,164)
|
|
(13.1)
|
|
14
|
|
16
|
|
13
|
|
Royalty
income
|
82
|
|
0.9
|
|
4
|
|
4
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
1,852
|
|
20.8
|
|
(16)
|
|
(11)
|
|
(17)
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
1,659
|
|
|
|
(18)
|
|
(13)
|
|
|
|
Adjusted
profit after tax
|
1,452
|
|
|
|
(13)
|
|
(8)
|
|
|
|
Adjusted
profit attributable to
shareholders
|
1,227
|
|
|
|
(20)
|
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
24.8p
|
|
|
|
(21)
|
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit by business
|
Q4 2019
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Reported
growth
CER%
|
|
Pro-forma
growth
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
1,935
|
|
42.5
|
|
(17)
|
|
(15)
|
|
(15)
|
|
Pharmaceuticals
R&D*
|
(927)
|
|
|
|
19
|
|
21
|
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Pharmaceuticals
|
1,008
|
|
22.1
|
|
(35)
|
|
(33)
|
|
(33)
|
|
Vaccines
|
578
|
|
33.2
|
|
38
|
|
42
|
|
42
|
|
Consumer
Healthcare
|
440
|
|
17.1
|
|
25
|
|
33
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,026
|
|
22.8
|
|
(13)
|
|
(10)
|
|
(15)
|
|
Corporate
& other unallocated
costs
|
(174)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
1,852
|
|
20.8
|
|
(16)
|
|
(11)
|
|
(17)
|
|
|
|
|
|
|
|
|
|
|
|
|
*
|
Operating
profit of Pharmaceuticals R&D segment, which is the
responsibility of the Chief Scientific Officer and President,
R&D. It excludes ViiV Healthcare R&D expenditure, which is
reported within the Pharmaceuticals segment.
|
|
Turnover
|
|
Pharmaceuticals turnover
|
|
|
Q4 2019
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Respiratory
|
892
|
|
8
|
|
9
|
|
HIV
|
1,257
|
|
(1)
|
|
-
|
|
Immuno-inflammation
|
170
|
|
25
|
|
26
|
|
Oncology
|
66
|
|
-
|
|
-
|
|
Established
Pharmaceuticals
|
2,173
|
|
(15)
|
|
(14)
|
|
|
|
|
|
|
|
|
|
4,558
|
|
(5)
|
|
(4)
|
|
|
|
|
|
|
|
|
US
|
1,958
|
|
(8)
|
|
(6)
|
|
Europe
|
1,048
|
|
(6)
|
|
(3)
|
|
International
|
1,552
|
|
(2)
|
|
-
|
|
|
|
|
|
|
|
|
|
4,558
|
|
(5)
|
|
(4)
|
|
|
|
|
|
|
|
|
Pharmaceuticals
turnover in the quarter was £4,558 million, down 5% AER, 4%
CER. Respiratory sales were up 8% AER, 9% CER to £892 million,
on growth of Trelegy
Ellipta and Nucala.
HIV sales of £1,257 million declined 1% AER but were flat at
CER, with growth in Juluca
and Dovato offset by a
decline in Tivicay. Sales
of Established Pharmaceuticals declined 15% AER, 14% CER to
£2,173 million, reflecting lower Advair sales following the generic
launch in Q1 2019. Established Pharmaceuticals growth in the
quarter was impacted by both a European Relenza tender and post divestment
inventory sales recorded in the prior year.
In the
US, sales declined 8% AER, 6% CER. Continued growth of Nucala, Trelegy Ellipta and Benlysta was more than offset by the
decline in Established Products, including the loss of exclusivity
of Advair. Excluding
Advair and Relvar/Breo Ellipta, which were
impacted by genericisation of the ICS/LABA market, growth was 7%
AER, 8% CER. In Europe, sales declined 6% AER, 3% CER, with strong
growth in Respiratory and from Zejula. International sales declined 2%
AER, but were flat at CER, with Respiratory growth offset by lower
Established Pharmaceutical sales reflecting post divestment
inventory sales in Q4 2018.
Respiratory
Total
Respiratory sales were up 8% AER, 9% CER, with strong growth in
Europe and International which saw growth in Ellipta products, including
Relvar/Breo and
Trelegy, and Nucala. Nucala sales grew 27% AER, 32% CER in
Europe and 36% AER, 36% CER in International. In the US,
Trelegy Ellipta and Nucala growth was offset by a decline
in Relvar/Breo Ellipta on
post-generic ICS/LABA price pressure.
Sales
of Nucala were £218
million in the quarter and grew 26% AER, 28% CER, with US sales up
23% AER, 24% CER to £132 million including the impact of the
new at-home use application.
Sales
of Ellipta products were up
3% AER, 4% CER to £674 million driven by growth in Europe and
International regions. In the US, sales declined 6% AER, 5% CER,
reflecting continued competitive pricing pressures for Relvar/Breo, partly offset by ongoing
growth in Trelegy Ellipta.
In Europe, Ellipta product
sales grew 17% AER, 19% CER. Sales of Trelegy Ellipta contributed £172
million globally in the quarter, driven by an increase in US market
share.
Relvar/Breo Ellipta sales were down 19% AER, 19% CER. In the
US, Relvar/Breo Ellipta
declined 42% AER, 41% CER impacted by US competitive pricing
pressures and the impact of generic Advair on the US ICS/LABA market. In
Europe and International, Relvar/Breo Ellipta continued to grow,
up 4% AER, 6% CER and 16% AER, 14% CER, respectively.
HIV
HIV
sales of £1,257 million declined 1% AER but were flat at CER
in the quarter. The dolutegravir franchise was flat at AER, but
grew 2% at CER, delivering sales of £1,208 million in the
quarter. The remaining portfolio, with sales of £49 million
and 4% of total HIV sales, declined 31% AER, 30% CER and reduced
the overall growth of total HIV by two percentage points in the
quarter.
Sales
of dolutegravir products were £1,208 million in the quarter,
with Triumeq and
Tivicay delivering sales of
£638 million and £426 million, respectively. The two-drug
regimens, Juluca and
Dovato, delivered sales of
£144 million in the quarter, with combined growth more than
offsetting the decline in the three-drug regimen, Triumeq, as the business transitions to
the new portfolio.
In the
US, following the launch of Dovato in April 2019, combined sales of
the two-drug regimens were £116 million. Total dolutegravir
sales were flat at AER but grew 2% at CER, reflecting a
year-on-year share decline as the business transitions to the new
two-drug portfolio, more than offset by net price benefit. In
Europe, total dolutegravir sales declined 4% AER, 1% CER, with
strong dolutegravir volume growth in the quarter more than offset
by price erosion, higher clawback payments, and an adverse stocking
pattern comparator in 2018. Combined sales of Dovato and Juluca recorded sales of £25
million. International continued to grow strongly with total
dolutegravir sales growth of 9% AER, 11% CER, driven by
Tivicay.
Oncology
Sales
of Zejula, the newly
acquired PARP inhibitor asset were £66 million in the quarter,
comprising £37 million in the US and £29 million in
Europe.
Immuno-inflammation
Sales
of Benlysta in the quarter
were up 23% AER, 24% CER to £170 million, including sales of
the sub-cutaneous formulation of £79 million. In the US,
Benlysta grew 22% AER, 25%
CER to £148 million.
Established
Pharmaceuticals
Sales
of Established Pharmaceuticals in the quarter were £2,173
million, down 15% AER, 14% CER.
Established
Respiratory products declined 17% AER, 16% CER to £965
million. In the US, Advair
experienced its third full quarter of generic competition,
resulting in a 65% AER, 64% CER decline. Also in the US,
Ventolin continued to
benefit from strong uptake of an authorised generic version
launched earlier in the year. In Europe, Seretide sales were down 21% AER, 18%
CER to £119 million, reflecting continued competition from
generic products and the transition of the Respiratory portfolio to
newer products. In International, sales of Seretide were down 4% AER, 4%
CER.
The
remainder of the Established Pharmaceuticals portfolio declined by
14% AER, 12% CER to £1,208 million including Lamictal down 9% AER, 8% CER to
£145 million on generic competition in the US and
International, partially offset by growth in Augmentin in International. Growth in
the quarter was impacted by a European Relenza tender and post divestment
inventory sales in the prior year.
|
|
Vaccines turnover
|
|
|
Q4 2019
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
Meningitis
|
203
|
|
8
|
|
14
|
|
Influenza
|
138
|
|
(28)
|
|
(26)
|
|
Shingles
|
532
|
|
>100
|
|
>100
|
|
Established
Vaccines
|
869
|
|
(1)
|
|
2
|
|
|
|
|
|
|
|
|
|
1,742
|
|
18
|
|
21
|
|
|
|
|
|
|
|
|
US
|
909
|
|
36
|
|
40
|
|
Europe
|
350
|
|
(7)
|
|
(4)
|
|
International
|
483
|
|
11
|
|
14
|
|
|
|
|
|
|
|
|
|
1,742
|
|
18
|
|
21
|
|
|
|
|
|
|
|
|
Vaccines
turnover grew 18% AER, 21% CER to £1,742 million, primarily
driven by growth in sales of Shingrix. Meningitis vaccines also
contributed to growth, mainly due to higher demand for Menveo in International. Influenza vaccines sales declined 28%
AER, 26% CER to £138 million, primarily due to the impact of
the favourable phasing in Q3 2019 in the US, despite further strong
sales execution. Established Vaccines were down 1% AER but grew 2%
CER to £869 million, reflecting higher sales of Synflorix, Hepatitis and Rotarix, partly offset by expected
returns on Cervarix due to
competitive pressure in China.
Meningitis
Meningitis
sales grew 8% AER, 14% CER to £203 million. Bexsero sales declined 2% AER but grew
5% CER to £112 million, driven by strong demand across
International and Europe and share gains in the US, partly offset
by lower channel inventory and an increased returns provision in
the US. Menveo grew 50%
AER, 57% CER, primarily reflecting higher demand and favourable
phasing in International, partly offset by lower US
sales.
Influenza
Fluarix/FluLaval sales declined 28% AER, 26% CER to
£138 million, primarily due to the impact of the favourable
phasing in Q3 2019 in the US, despite further strong sales
execution.
Shingles
Shingrix recorded sales of £532 million in the quarter,
driven by continued strong uptake and the benefit of prior-period
rebate adjustments in the US. Germany and Canada also contributed
to growth.
Established
Vaccines
Sales
of DTPa-containing vaccines (Infanrix, Pediarix and Boostrix) declined 6% AER, 3% CER.
Infanrix, Pediarix sales were down 5% AER, 2% CER
to £156 million, reflecting competitive pressures and
unfavourable phasing in Europe together with lower demand in the
US, partly offset by stronger demand in International. Boostrix sales declined 6% AER, 4% CER
to £130 million, mainly due to the reversal of favourable
phasing in International in Q3 2019, partly offset by higher demand
and share gains in the US.
Hepatitis vaccines grew 3% AER, 6% CER to £195 million,
primarily due to the continued benefit from a competitor supply
shortage in the US and favourable supply phasing in International,
partly offset by lower demand in Europe.
Rotarix sales were up 5% AER, 8% CER to £141 million,
reflecting stronger demand in the US.
Synflorix sales grew 17% AER, 20% CER to £124 million
due to higher demand in International, partly offset by lower
demand in Europe.
MMRV
vaccines sales were up 10% AER, 11% CER to £70 million, mainly
driven by higher demand in International, partly offset by supply
constraints in Europe.
|
|
Consumer Healthcare turnover
|
|
|
|
|
Q4 2019
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Wellness
|
|
|
1,294
|
|
29
|
|
31
|
|
Oral
health
|
|
|
651
|
|
4
|
|
7
|
|
Nutrition
|
|
|
463
|
|
>100
|
|
>100
|
|
Skin
health
|
|
|
163
|
|
29
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,571
|
|
35
|
|
37
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
889
|
|
82
|
|
81
|
|
Europe
|
|
|
621
|
|
14
|
|
17
|
|
International
|
|
|
1,061
|
|
21
|
|
25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,571
|
|
35
|
|
37
|
|
|
|
|
|
|
|
|
|
|
Pro-forma
growth
|
|
|
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Consumer
Healthcare sales grew 35% AER, 37% CER to £2,571 million in the quarter. On a
pro-forma basis, sales were flat, with strong growth in Oral health offset by
declines in other categories partly due to the alignment of
in-market inventory levels of some Pfizer
brands.
Divestments and the phasing out of low margin contract
manufacturing had a negative impact of approximately one percentage
point on pro-forma growth.
The
legacy Pfizer brands have been included in the existing categories
and geographic regions used to report Consumer Healthcare
sales. GSK expects to revise this
category structure for reporting from Q1 2020
onwards.
Wellness
Wellness
sales grew 29% AER, 31% CER to £1,294 million in the quarter. On a
pro-forma basis, sales declined in low single digits, with growth
in Pain relief offset by a decline in Respiratory and the
phasing out of low margin contract
manufacturing. In Pain relief, Panadol continued to perform strongly,
particularly in the Middle East and Africa, and benefited from 2018 regulatory and
distribution changes. Advil
growth reflected ongoing recovery from now resolved supply issues.
Pain relief growth was partly offset by a decline in Voltaren, partly reflecting retail
stock movements.
Oral
health
Oral
health grew 4% AER, 7% CER to £651 million with strong performance across
the category, benefiting from a number of new product innovations
during the year. Sensodyne and Gum health saw double-digit,
broad-based growth, while Denture care grew in low single
digits.
Nutrition
Nutrition
sales more than doubled at both AER and CER in the quarter to
£463 million, largely due
to the inclusion of the Pfizer vitamins, minerals and supplements
portfolio. On a pro-forma basis, sales
declined in low single digits, due to the alignment of
in-market inventory levels of some Pfizer brands.
Skin
health
Skin
health sales grew 29%
AER, 32% CER to £163 million, largely due to the addition of
Chapstick from the Pfizer
portfolio. On a pro-forma basis, a
decline in sales largely reflected divestments of small tail
brands in the US and UK.
|
|
Operating performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 36.5%, 1.1 percentage
points higher at AER and 1.1 percentage points higher in CER terms
compared with Q4 2018. This reflected the unwind of the fair market
value uplift on inventory arising on completion of the Consumer
Healthcare Joint Venture with Pfizer and increased amortisation of
intangible assets, partly offset by a reduction in the costs of
manufacturing restructuring programmes, primarily as a result of
write downs in a number of manufacturing sites in Q4
2018
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 32.0%, 1.1 percentage points higher at
AER, and 1.1 percentage points higher at CER compared with Q4 2018.
On a pro-forma basis, Adjusted cost of sales as a percentage of
turnover was 32.0%, 0.7% percentage points higher at CER compared
with Q4 2018. The increase reflected continued adverse pricing
pressure in Pharmaceuticals, particularly in Respiratory, and a
non-restructuring related write down in a manufacturing site. This
was partly offset by more favourable product mixes in
Pharmaceuticals, due to a reduction in sales of some lower margin
established products, and Vaccines, primarily due to the growth of
Shingrix in the
US.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 38.7%, 6.7
percentage points higher at AER and 6.0 percentage points higher on
a CER basis compared with Q4 2018. This included increased Major
restructuring costs primarily related to integration of the
Consumer Healthcare Joint Venture with Pfizer as well as increased
significant legal costs primarily reflecting settlement of existing
matters, partly offset by reduced acquisition costs for Tesaro
compared with Q4 2018.
Excluding
these and other Adjusting items, Adjusted SG&A costs as a
percentage of turnover were 35.0%, 4.2 percentage points higher at
AER than in Q4 2018 and 3.5 percentage points higher on a CER
basis. On a pro-forma basis, Adjusted SG&A costs as a
percentage of turnover were 35.0%, 2.8 percentage points higher at
CER compared with Q4 2018. The growth in Adjusted SG&A costs of
23% AER, 23% CER, (11% CER pro-forma) reflected increased
investment resulting from the acquisition of Tesaro and in
promotional product support, particularly for new launches in
Respiratory, HIV and Vaccines. This was partly offset by the
continuing benefit of restructuring in Pharmaceuticals and the
tight control of ongoing costs, particularly in non-promotional
spending, across all three businesses.
Research and development
Total
R&D expenditure was £1,243 million (14.0% of turnover), up
16% AER, 17% CER. Adjusted R&D expenditure was £1,164
million (13.1% of turnover), 14% higher at AER, 16% higher at CER
than Q4 2018. On a pro-forma basis, Adjusted R&D expenditure
was 13% higher at CER compared with Q4 2018.
Pharmaceuticals
R&D expenditure was £899 million, up 13% AER, 15% CER,
reflecting a significant increase in Oncology investment including
the assets from the Tesaro acquisition (primarily Zejula and dostarlimab) and a number of
other mid and late-stage programmes including belantamab mafodotin,
NY-ESO, ICOS and bintrafusp alfa, as well as increased spending on
the progression of key non-Oncology assets, such as aGM-CSF for
rheumatoid arthritis. This was partly offset by a favourable
comparison with Q4 2018 as a result of significant portfolio
reprioritisation. R&D expenditure in Vaccines and Consumer
Healthcare was £186 million and £79 million,
respectively.
|
|
Royalty income
Royalty
income was £82 million (Q4 2018: £79 million), up 4% AER,
4% CER, primarily reflecting increased royalties on sales of
Gardasil.
Other operating income/(expense)
Net
other operating income of £855 million (Q4 2018: £122
million expense) primarily reflected net accounting credits of
£535 million (Q4 2018: £229 million charges) arising from
the re-measurement of the contingent consideration liabilities
related to the acquisitions of the former Shionogi-ViiV Healthcare
joint venture and the former Novartis Vaccines business and the
liabilities for the Pfizer put option and Pfizer and Shionogi
preferential dividends in ViiV Healthcare. This included a
re-measurement credit of £390 million (Q4 2018: £261
million charge) for the contingent consideration liability due to
Shionogi, primarily arising from changes in exchange rate
assumptions and forecast assumptions, partly offset by the unwind
of the discount.
Other
income also included the profit on disposal of the rabies and
tick-borne encephalitis vaccines (£306 million) and a number
of other asset disposals. This was partly offset by a decrease in
value of the shares in Hindustan Unilever Limited to be received on
the disposal of Horlicks
and other Consumer Healthcare brands of £105 million in the
quarter. The cumulative increase in value since the signing of the
proposed transaction was £240 million.
|
|
Operating profit
Total
operating profit was £1,902 million in Q4 2019 compared with
£1,554 million in Q4 2018. Re-measurement credits on the
contingent consideration liabilities, increased profit on disposals
and reduced restructuring costs were partly offset by a decrease in
the value of the shares in Hindustan Unilever Limited to be
received on the disposal of Horlicks and other Consumer Healthcare
brands and the unwind of the fair market value uplift on inventory
arising on completion of the Consumer Healthcare Joint Venture with
Pfizer.
Excluding
these and other Adjusting items, Adjusted operating profit was
£1,852 million, 16% lower than Q4 2018 at AER and 11% lower at
CER on a turnover increase of 11% CER. The Adjusted operating
margin of 20.8% was 6.0 percentage points lower at AER and 5.2
percentage points lower on a CER basis than in Q4 2018. On a
pro-forma basis, Adjusted operating profit was 17% lower at CER on
a turnover increase of 2% CER. The Adjusted pro-forma operating
margin of 20.8% was 4.8 percentage points lower on a CER basis than
in Q4 2018.
The
reduction in Adjusted operating profit primarily reflected
increased investment in R&D, including a significant increase
in Oncology, partly on the assets from the Tesaro acquisition,
investments in promotional product support, particularly for new
launches in Vaccines, HIV and Respiratory, as well as continuing
price pressure, particularly in Respiratory, including the impact
of the launch of a generic version of Advair in the US in February 2019,
together with a non-restructuring related write down in a
manufacturing site. This was partly offset by the benefit from
sales growth, particularly in Vaccines, a more favourable mix in
Vaccines and continued tight control of ongoing costs, particularly
in non-promotional spending, across all three
businesses.
Contingent
consideration cash payments which are made to Shionogi and other
companies reduce the balance sheet liability and hence are not
recorded in the income statement. Total contingent consideration
cash payments in the quarter amounted to £233 million (Q4
2018: £222 million). This included cash payments made to
Shionogi of £220 million (Q4 2018: £209
million).
Operating profit by business
Pharmaceuticals
operating profit was £1,008 million, down 35% AER, 33% CER on
a turnover decrease of 4% CER. The operating margin of 22.1% was
10.4 percentage points lower at AER than in Q4 2018 and 10.0
percentage points lower on a CER basis. This primarily reflected a
significant increase in R&D investment, particularly in
Oncology, and investment in new product support and targeted
priority markets, as well as the continued impact of lower prices,
particularly in Respiratory, including the impact of the launch of
a generic version of Advair
in the US in February 2019 and a non-restructuring related write
down in a manufacturing site. This was partly offset by a
favourable product mix, primarily due to a reduction in some lower
margin established products, tight control of ongoing costs and the
benefits of re-prioritisation of the R&D
portfolio.
Vaccines operating profit was £578 million, 38% higher than Q4
2018 at AER and 42% higher at CER on a turnover increase of 21%
CER. The operating margin of 33.2% was 4.8 percentage points higher
than in Q4 2018 at AER and 4.9 percentage points higher on a CER
basis. This was primarily driven by enhanced operating leverage
from strong sales growth, particularly Shingrix in the US, and improved product mix, partly offset
by higher supply chain costs.
Consumer
Healthcare operating profit was £440 million, up 25% AER, 33%
CER on a turnover increase of 37% CER. On a pro-forma basis
operating profit of £440 million was down 8% CER with turnover
flat at CER. The operating margin of 17.1% was 1.3 percentage
points lower at AER and 0.6 percentage points lower on a CER basis.
The pro-forma operating margin of 17.1% was 1.6 percentage points
lower on a CER basis than in Q4 2018. This primarily reflected
reduced growth from higher margin power brands in the quarter
following earlier seasonal sell-ins, increased promotional
investment and unfavourable inventory adjustments, partly offset by
continued manufacturing restructuring savings. Growth was also
adversely affected by a different central cost allocation
methodology applied by Pfizer in the comparative pro-forma
financial information.
Net finance costs
Total
net finance costs were £195 million compared with £185
million in Q4 2018. Adjusted net finance costs were £197
million compared with £173 million in Q4 2018. The increase
primarily reflected higher debt levels reflecting the acquisition
of Tesaro in January 2019. Following the introduction of IFRS 16,
‘Leases’, finance costs included an unwind of the
discount on the lease liability of £10 million in the
quarter.
Share of after tax profits of associates and joint
ventures
The
share of after tax profits of associates was £4 million (Q4
2018: £5 million).
Taxation
The
charge of £194 million represented an effective tax rate on
Total results of 11.3% (Q4 2018: 5.4%) and reflected the different
tax effects of the various Adjusting items. Tax on Adjusted profit
amounted to £207 million and represented an effective Adjusted
tax rate of 12.5% (Q4 2018: 17.5%), reflecting the impact of the
settlement of a number of open issues with tax
authorities.
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2018. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods which are open and not yet
agreed by tax authorities. The ultimate liability for such matters
may vary from the amounts provided and is dependent upon the
outcome of agreements with relevant tax authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £218 million (Q4 2018: £85 million). The increase was
primarily due to an increased allocation of ViiV Healthcare profits
of £192 million (Q4 2018: £78 million) including charges
for movements in contingent consideration liabilities and the
allocation of Pfizer’s interest in the profits of the
Consumer Healthcare Joint Venture (£23 million), partly offset
by lower net profits in some of the Group’s other entities
with non-controlling interests.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £225 million (Q4 2018: £139 million). The
increase in allocation was primarily due to the allocation of
Pfizer’s interest in the profits of the Consumer Healthcare
Joint Venture (£101 million), partly offset by a reduced
allocation of ViiV Healthcare profits of £121 million (Q4
2018: £130 million) and lower net profits in some of the
Group’s other entities with non-controlling
interests.
Earnings per share
Total
earnings per share was 26.2p, compared with 24.7p in Q4 2018. The
increase in earnings per share primarily reflected re-measurement
credits on the contingent consideration liabilities, increased
profit on disposals and reduced restructuring costs, partly offset
by a decrease in the value of the shares in Hindustan Unilever
Limited to be received on the disposal of Horlicks and other Consumer Healthcare
brands and the unwind of the fair market value uplift on inventory
arising on completion of the Consumer Healthcare Joint Venture with
Pfizer.
Adjusted
EPS of 24.8p compared with 31.2p in Q4 2018, down 21% AER, 16% CER,
on an 11% CER decrease in Adjusted operating profit. This reflected
an increased non-controlling interest allocation of Consumer
Healthcare profits following the creation of the new Consumer
Healthcare Joint Venture in Q3 2019 and increased net finance
costs, partly offset by a reduced effective tax rate.
Currency impact on Q4 2019 results
The Q4
2019 results are based on average exchange rates, principally
£1/$1.30, £1/€1.17 and £1/Yen 141. Comparative
exchange rates are given on page 56. The period-end exchange rates
were £1/$1.32, £1/€1.18 and £1/Yen
143.
In the
quarter, turnover increased 9% AER, 11% CER. Total EPS was 26.2p
compared with 24.7p in Q4 2018. Adjusted EPS was 24.8p compared
with 31.2p in Q4 2018, down 21% AER, 16% CER. The negative currency
impact primarily reflected the strength of Sterling, particularly
against the US$, Euro and emerging market currencies, relative to
Q4 2018. Exchange gains or losses on the settlement of intercompany
transactions represented one percentage point of the negative
currency impact of five percentage points on Adjusted
EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for Q4
2019 and Q4 2018 are set out below.
|
|
Three months ended 31 December 2019
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
8,899
|
|
|
|
|
|
8,899
|
|
Cost of sales
|
(3,248)
|
163
|
3
|
11
|
223
|
|
(2,848)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
5,651
|
163
|
3
|
11
|
223
|
|
6,051
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(3,443)
|
|
(1)
|
163
|
4
|
160
|
(3,117)
|
|
Research and development
|
(1,243)
|
16
|
19
|
43
|
|
1
|
(1,164)
|
|
Royalty income
|
82
|
|
|
|
|
|
82
|
|
Other operating income/(expense)
|
855
|
|
|
|
(557)
|
(298)
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
1,902
|
179
|
21
|
217
|
(330)
|
(137)
|
1,852
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(195)
|
|
|
1
|
|
(3)
|
(197)
|
|
Share of after tax profits of
associates and joint ventures
|
4
|
|
|
|
|
|
4
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
1,711
|
179
|
21
|
218
|
(330)
|
(140)
|
1,659
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(194)
|
(41)
|
(6)
|
(58)
|
15
|
77
|
(207)
|
|
Tax rate %
|
11.3%
|
|
|
|
|
|
12.5%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
1,517
|
138
|
15
|
160
|
(315)
|
(63)
|
1,452
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
218
|
|
|
|
7
|
|
225
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
1,299
|
138
|
15
|
160
|
(322)
|
(63)
|
1,227
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
26.2p
|
2.8p
|
0.3p
|
3.2p
|
(6.5)p
|
(1.2)p
|
24.8p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of
shares (millions)
|
4,953
|
|
|
|
|
|
4,953
|
|
|
––––––––––––
|
|
|
|
|
|
––––––––––––
|
|
Three months ended 31 December 2018
|
|
|
Total
results
£m
|
Intangible
amort-
isation
£m
|
Intangible
impair-
ment
£m
|
Major
restruct-
uring
£m
|
Transaction-
related
£m
|
Divestments,
significant
legal and
other items
£m
|
Adjusted
results
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Turnover
|
8,197
|
|
|
|
|
|
8,197
|
|
Cost of sales
|
(2,904)
|
136
|
|
232
|
4
|
|
(2,532)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Gross profit
|
5,293
|
136
|
|
232
|
4
|
|
5,665
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(2,620)
|
|
|
48
|
37
|
6
|
(2,529)
|
|
Research and development
|
(1,076)
|
14
|
12
|
22
|
|
9
|
(1,019)
|
|
Royalty income
|
79
|
|
|
|
|
|
79
|
|
Other operating (expense)/income
|
(122)
|
|
|
1
|
230
|
(109)
|
-
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Operating profit
|
1,554
|
150
|
12
|
303
|
271
|
(94)
|
2,196
|
|
|
|
|
|
|
|
|
|
|
Net finance costs
|
(185)
|
|
|
2
|
(3)
|
13
|
(173)
|
|
Share of after tax profits of
associates and joint ventures
|
5
|
|
|
|
|
|
5
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit before taxation
|
1,374
|
150
|
12
|
305
|
268
|
(81)
|
2,028
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(74)
|
(24)
|
(4)
|
(48)
|
(38)
|
(167)
|
(355)
|
|
Tax rate %
|
5.4%
|
|
|
|
|
|
17.5%
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit after taxation
|
1,300
|
126
|
8
|
257
|
230
|
(248)
|
1,673
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Profit
attributable to
non-controlling
interests
|
85
|
|
|
|
54
|
|
139
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to
shareholders
|
1,215
|
126
|
8
|
257
|
176
|
(248)
|
1,534
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
24.7p
|
2.6p
|
0.2p
|
5.2p
|
3.6p
|
(5.1)p
|
31.2p
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of
shares (millions)
|
4,920
|
|
|
|
|
|
4,920
|
|
|
––––––––––––
|
|
|
|
|
|
––––––––––––
|
|
Major restructuring and integration
Within the Pharmaceuticals sector, the highly regulated
manufacturing operations and supply chains and long lifecycle of
the business mean that restructuring programmes, particularly those
that involve the rationalisation or closure of manufacturing or
R&D sites are likely to take several years to
complete.
|
|
Total
Major restructuring charges incurred in the quarter were £217
million (Q4 2018: £303 million), analysed as
follows:
|
|
|
Q4 2019
|
|
Q4
2018
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018
major restructuring
programme
(incl. Tesaro)
|
48
|
|
23
|
|
71
|
|
151
|
|
90
|
|
241
|
|
Consumer
Healthcare Joint
Venture
integration
Programme
|
113
|
|
4
|
|
117
|
|
-
|
|
-
|
|
-
|
|
Combined
restructuring and
integration
programme
|
18
|
|
11
|
|
29
|
|
52
|
|
10
|
|
62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179
|
|
38
|
|
217
|
|
203
|
|
100
|
|
303
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges arose from integration costs under the Consumer Healthcare
Joint Venture integration programme as well as restructuring of the
manufacturing organisation, R&D and some administrative
functions, and the integration of Tesaro under the 2018 major
restructuring programme. Non-cash charges arising under the 2018
major restructuring programme and Combined restructuring and
integration programme primarily related to the write-down of assets
as part of announced plans to reduce the manufacturing
network.
Total
cash payments made in the quarter were £255 million, £69
million for the existing Combined restructuring and integration
programme (Q4 2018: £175 million) and £79 million under
the 2018 major restructuring programme (Q4 2018: £9 million),
including the settlement of certain charges accrued in previous
quarters, and a further £107 million relating to the Consumer
Healthcare Joint Venture integration programme.
The
analysis of Major restructuring charges by business was as
follows:
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
|
|
|
|
|
Pharmaceuticals
|
36
|
|
269
|
|
Vaccines
|
10
|
|
28
|
|
Consumer
Healthcare
|
134
|
|
(28)
|
|
|
|
|
|
|
|
180
|
|
269
|
|
Corporate
& central functions
|
37
|
|
34
|
|
|
|
|
|
|
Total
Major restructuring costs
|
217
|
|
303
|
|
|
|
|
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
|
|
|
|
|
Cost of
sales
|
11
|
|
232
|
|
Selling,
general and administration
|
163
|
|
48
|
|
Research
and development
|
43
|
|
22
|
|
Other
operating expense
|
-
|
|
1
|
|
|
|
|
|
|
Total
Major restructuring costs
|
217
|
|
303
|
|
|
|
|
|
|
The
Major restructuring programmes delivered incremental cost savings
in the quarter of £0.2 billion.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net credit of £330 million (Q4 2018:
£271 million charge). This primarily reflected £535
million of net accounting credits for the re-measurement of the
contingent consideration liabilities related to the acquisitions of
the former Shionogi-ViiV Healthcare joint venture and the former
Novartis Vaccines business and the liabilities for the Pfizer put
option and Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
(Credit)/charge
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
venture
(including
Shionogi preferential dividends)
|
(390)
|
|
261
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
(153)
|
|
(40)
|
|
Contingent
consideration on former Novartis Vaccines business
|
8
|
|
8
|
|
Release
of fair value uplift on acquired Pfizer inventory
|
218
|
|
-
|
|
Other
adjustments
|
(13)
|
|
42
|
|
|
|
|
|
|
Total
transaction-related charges
|
(330)
|
|
271
|
|
|
|
|
|
|
The
£390 million credit relating to the contingent consideration
for the former Shionogi-ViiV Healthcare joint venture represented a
decrease in the valuation of the contingent consideration due to
Shionogi, primarily as a result of updated exchange rate
assumptions as well as sales forecasts, partly offset by a
£112 million unwind of the discount.
An
explanation of the accounting for the non-controlling interests in
ViiV Healthcare is set out on page 10.
Divestments, significant legal charges and other items
Divestments
and other items included a profit on the disposal of the rabies and
tick-borne encephalitis vaccines (£306 million) and a number
of other assets, partly offset by a loss in the quarter of
£105 million arising from the decrease in value of the shares
in Hindustan Unilever Limited to be received on the disposal of
Horlicks and other Consumer
Healthcare brands and a charge of £164 million (Q4 2018:
£4 million) for significant legal matters reflecting the
settlement of existing matters as well as provisions for ongoing
litigation. Significant legal cash payments were £281 million
(Q4 2018: £15 million).
|
|
Cash generation
|
|
Cash flow
|
|
|
2019
|
|
2018
|
|
Q4
2019
|
|
|
|
|
|
|
|
|
Net
cash inflow from operating activities (£m)
|
8,020
|
|
8,421
|
|
3,453
|
|
Free
cash flow* (£m)
|
5,073
|
|
5,692
|
|
2,599
|
|
Free
cash flow growth (%)
|
(11)%
|
|
63%
|
|
(22)%
|
|
Free
cash flow conversion* (%)
|
>100%
|
|
>100%
|
|
>100%
|
|
Net
debt** (£m)
|
25,215
|
|
21,621
|
|
25,215
|
|
*
|
Free
cash flow and free cash flow conversion are defined on page
60.
|
|
**
|
Net
debt is analysed on page 59.
|
|
2019
The net
cash inflow from operating activities for the year was £8,020
million (2018: £8,421 million). Free cash flow was £5,073
million (2018: £5,692 million). The reduction primarily
reflected the adverse timing of payments for returns and rebates,
as well as the initial step-down impact from US Advair generic competition, increased
capital expenditure including the acquisition of intangible assets,
higher restructuring payments and higher significant legal costs.
This was partly offset by improved operating profits including
currency benefits, a reduction in inventory and lower increase in
trade receivables, lower contingent consideration payments compared
with 2018, which included a milestone payment to Novartis, lower
dividend payments to non-controlling interests and the
reclassification of lease payments from operating to financing
activities following the transition to IFRS 16.
Total
cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the year were £865
million (2018: £793 million), of which £767 million was
recognised in cash flows from operating activities and £98
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
|
|
Q4 2019
Net
cash inflow from operating activities for the quarter was
£3,453 million (Q4 2018: £4,119 million). Free cash flow
was £2,599 million (Q4 2018: £3,317 million). The
reduction primarily reflected the adverse timing of payments for
returns and rebates and the step-down impact from US Advair generic competition, higher
significant legal payments and lower operating profits including
the effects of currency. This was partly offset by a greater
seasonal reduction in inventory and trade receivables and the
reclassification of lease payments from operating to financing
activities following the transition to IFRS 16.
Total
cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the quarter were £220
million (Q4 2018: £209 million), of which £195 million
was recognised in cash flows from operating activities and £25
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
|
|
Net debt
At 31
December 2019, net debt was £25.2 billion, compared with
£21.6 billion at 31 December 2018, comprising gross debt of
£30.5 billion and cash and liquid investments of £5.3
billion, including £0.5 billion reported within Assets held
for sale. Net debt increased due to the £3.9 billion
acquisition of Tesaro Inc as well as £0.2 billion of Tesaro
net debt, together with the £1.3 billion impact from the
implementation of IFRS 16, the dividend paid to shareholders of
£4.0 billion and other net investing activities of £0.1
billion, partly offset by £0.7 billion net favourable exchange
impacts from the translation of non-Sterling denominated debt and
exchange on other financing items and £5.1 billion of free
cash flow.
At 31
December 2019, GSK had short-term borrowings (including overdrafts
and lease liabilities) repayable within 12 months of £6.9
billion with loans of £3.2 billion repayable in the subsequent
year.
|
|
Returns to shareholders
|
|
Quarterly dividends
The
Board has declared a fourth interim dividend for 2019 of 23 pence
per share (Q4 2018: 23 pence per share).
GSK
recognises the importance of dividends to shareholders and aims to
distribute regular dividend payments that will be determined
primarily with reference to the free cash flow generated by the
business after funding the investment necessary to support the
Group’s future growth.
The
Board intends to maintain the dividend for 2020 at the current
level of 80p per share, subject to any material change in the
external environment or performance expectations. Over time, as
free cash flow strengthens, it intends to build free cash flow
cover of the annual dividend to a target range of 1.25-1.50x,
before returning the dividend to growth.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 7 April 2020. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) (2018: $0.02
per ADS; $0.005 per ADS per quarter) is charged by the
Depositary.
The
ex-dividend date will be 20 February 2020, with a record date of 21
February 2020 and a payment date of 9 April 2020.
|
|
|
Paid/
payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2019
|
|
|
|
|
|
|
First
interim
|
11 July
2019
|
|
19
|
|
940
|
|
Second
interim
|
10
October 2019
|
|
19
|
|
941
|
|
Third
interim
|
9
January 2020
|
|
19
|
|
941
|
|
Fourth
interim
|
9 April
2020
|
|
23
|
|
1,139
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
3,961
|
|
|
|
|
|
|
|
|
2018
|
|
|
|
|
|
|
First
interim
|
12 July
2018
|
|
19
|
|
934
|
|
Second
interim
|
11 October
2018
|
|
19
|
|
934
|
|
Third
interim
|
10 January
2019
|
|
19
|
|
935
|
|
Fourth
interim
|
11 April
2019
|
|
23
|
|
1,137
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
3,940
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|
|
|
|
|
|
|
|
|
2019
millions
|
|
2018
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,947
|
|
4,914
|
|
Dilutive
effect of share options and share awards
|
|
|
69
|
|
57
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
5,016
|
|
4,971
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|
|
|
|
|
|
|
|
|
Q4 2019
millions
|
|
Q4
2018
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
4,953
|
|
4,920
|
|
Dilutive
effect of share options and share awards
|
|
|
69
|
|
58
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
5,022
|
|
4,978
|
|
|
|
|
|
|
|
|
At 31
December 2019, 4,953 million shares (2018: 4,923 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). GSK made no share repurchases during the year. The company
issued 4.0 million shares under employee share schemes in the year
for proceeds of £51 million (2018: £74
million).
|
|
At 31 December 2019, the ESOP Trust held 36.0 million GSK shares
against the future exercise of share options and share awards. The
carrying value of £135 million has been deducted from other
reserves. The market value of these shares was £647
million.
At 31 December 2019, the company held 393.5 million Treasury shares
at a cost of £5,505 million, which has been deducted from
retained earnings.
|
|
Financial information
|
|
Income statements
|
|
|
2019
£m
|
|
2018
£m
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
|
|
|
|
|
|
|
|
|
TURNOVER
|
33,754
|
|
30,821
|
|
8,899
|
|
8,197
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(11,863)
|
|
(10,241)
|
|
(3,248)
|
|
(2,904)
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
21,891
|
|
20,580
|
|
5,651
|
|
5,293
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(11,402)
|
|
(9,915)
|
|
(3,443)
|
|
(2,620)
|
|
Research
and development
|
(4,568)
|
|
(3,893)
|
|
(1,243)
|
|
(1,076)
|
|
Royalty income
|
351
|
|
299
|
|
82
|
|
79
|
|
Other
operating income/(expense)
|
689
|
|
(1,588)
|
|
855
|
|
(122)
|
|
|
|
|
|
|
|
|
|
|
OPERATING PROFIT
|
6,961
|
|
5,483
|
|
1,902
|
|
1,554
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
98
|
|
81
|
|
11
|
|
24
|
|
Finance
expense
|
(912)
|
|
(798)
|
|
(206)
|
|
(209)
|
|
Profit
on disposal of associates
|
-
|
|
3
|
|
-
|
|
-
|
|
Share
of after tax profits of
associates
and joint ventures
|
74
|
|
31
|
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
6,221
|
|
4,800
|
|
1,711
|
|
1,374
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(953)
|
|
(754)
|
|
(194)
|
|
(74)
|
|
Tax rate %
|
15.3%
|
|
15.7%
|
|
11.3%
|
|
5.4%
|
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
5,268
|
|
4,046
|
|
1,517
|
|
1,300
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
623
|
|
423
|
|
218
|
|
85
|
|
Profit
attributable to shareholders
|
4,645
|
|
3,623
|
|
1,299
|
|
1,215
|
|
|
|
|
|
|
|
|
|
|
|
5,268
|
|
4,046
|
|
1,517
|
|
1,300
|
|
|
|
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
93.9p
|
|
73.7p
|
|
26.2p
|
|
24.7p
|
|
|
|
|
|
|
|
|
|
|
Diluted
earnings per share
|
92.6p
|
|
72.9p
|
|
25.9p
|
|
24.4p
|
|
|
|
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
Profit
for the year
|
5,268
|
|
4,046
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
(832)
|
|
(480)
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas
subsidiaries
|
(75)
|
|
-
|
|
Fair
value movements on cash flow hedges
|
(20)
|
|
140
|
|
Reclassification
of cash flow hedges to income statement
|
3
|
|
(175)
|
|
Deferred
tax on fair value movements on cash flow hedges
|
16
|
|
(22)
|
|
Deferred
tax reversed on reclassification of cash flow hedges
|
-
|
|
20
|
|
|
|
|
|
|
|
(908)
|
|
(517)
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
(75)
|
|
(1)
|
|
Fair
value movements on equity investments
|
372
|
|
180
|
|
Deferred
tax on fair value movements on equity investments
|
(95)
|
|
10
|
|
Re-measurement
(losses)/gains on defined benefit plans
|
(1,050)
|
|
728
|
|
Tax on
re-measurement (losses)/gains on defined benefit plans
|
189
|
|
(146)
|
|
|
|
|
|
|
|
(659)
|
|
771
|
|
|
|
|
|
|
Other
comprehensive (expense)/income for the year
|
(1,567)
|
|
254
|
|
|
|
|
|
|
Total
comprehensive income for the year
|
3,701
|
|
4,300
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the year attributable to:
|
|
|
|
|
Shareholders
|
3,153
|
|
3,878
|
|
Non-controlling
interests
|
548
|
|
422
|
|
|
|
|
|
|
|
3,701
|
|
4,300
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
|
|
|
|
|
Profit
for the period
|
1,517
|
|
1,300
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
(637)
|
|
(112)
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas
subsidiaries
|
(75)
|
|
-
|
|
Fair
value movements on cash flow hedges
|
86
|
|
(42)
|
|
Reclassification
of cash flow hedges to income statement
|
-
|
|
(11)
|
|
Deferred
tax on fair value movements on cash flow hedges
|
16
|
|
2
|
|
|
|
|
|
|
|
(610)
|
|
(163)
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
(103)
|
|
18
|
|
Fair
value movements on equity investments
|
276
|
|
(88)
|
|
Deferred
tax on fair value movements on equity investments
|
(68)
|
|
23
|
|
Re-measurement
gains/(losses) on defined benefit plans
|
142
|
|
(375)
|
|
Tax on
re-measurement gains/(losses) on defined benefit plans
|
(26)
|
|
59
|
|
|
|
|
|
|
|
221
|
|
(363)
|
|
|
|
|
|
|
Other
comprehensive expense for the period
|
(389)
|
|
(526)
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
1,128
|
|
774
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
1,013
|
|
671
|
|
Non-controlling
interests
|
115
|
|
103
|
|
|
|
|
|
|
|
1,128
|
|
774
|
|
|
|
|
|
|
Pharmaceuticals turnover – year ended 31 December
2019
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
3,081
|
18
|
15
|
1,742
|
10
|
6
|
783
|
29
|
29
|
556
|
33
|
31
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Ellipta
products
|
2,313
|
13
|
10
|
1,289
|
4
|
-
|
577
|
26
|
27
|
447
|
29
|
27
|
|
Anoro Ellipta
|
514
|
8
|
5
|
324
|
2
|
(2)
|
120
|
19
|
20
|
70
|
23
|
21
|
|
Arnuity Ellipta
|
48
|
9
|
5
|
41
|
5
|
3
|
-
|
-
|
-
|
7
|
40
|
20
|
|
Incruse Ellipta
|
262
|
(8)
|
(10)
|
161
|
(13)
|
(17)
|
73
|
(1)
|
(1)
|
28
|
17
|
17
|
|
Relvar/Breo Ellipta
|
971
|
(11)
|
(13)
|
381
|
(34)
|
(37)
|
282
|
11
|
12
|
308
|
21
|
19
|
|
Trelegy Ellipta
|
518
|
>100
|
>100
|
382
|
>100
|
>100
|
102
|
>100
|
>100
|
34
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala
|
768
|
36
|
33
|
453
|
33
|
28
|
206
|
36
|
37
|
109
|
56
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
4,854
|
3
|
1
|
3,004
|
3
|
(1)
|
1,156
|
(3)
|
(2)
|
694
|
13
|
13
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Dolutegravir
products
|
4,633
|
5
|
2
|
2,938
|
4
|
-
|
1,086
|
-
|
-
|
609
|
22
|
22
|
|
Tivicay
|
1,662
|
1
|
(1)
|
977
|
(6)
|
(9)
|
395
|
5
|
6
|
290
|
28
|
28
|
|
Triumeq
|
2,549
|
(4)
|
(6)
|
1,611
|
(4)
|
(7)
|
626
|
(11)
|
(11)
|
312
|
15
|
15
|
|
Juluca
|
366
|
>100
|
>100
|
303
|
>100
|
>100
|
56
|
>100
|
>100
|
7
|
>100
|
>100
|
|
Dovato
|
56
|
-
|
-
|
47
|
-
|
-
|
9
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
75
|
(36)
|
(35)
|
3
|
(57)
|
(57)
|
23
|
(48)
|
(48)
|
49
|
(26)
|
(24)
|
|
Selzentry
|
97
|
(16)
|
(17)
|
53
|
(9)
|
(12)
|
29
|
(17)
|
(14)
|
15
|
(32)
|
(32)
|
|
Other
|
49
|
(30)
|
(31)
|
10
|
(44)
|
(44)
|
18
|
(25)
|
(29)
|
21
|
(25)
|
(25)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
613
|
30
|
25
|
535
|
27
|
23
|
46
|
28
|
28
|
32
|
>100
|
94
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Benlysta
|
613
|
30
|
25
|
535
|
27
|
23
|
46
|
24
|
24
|
32
|
>100
|
94
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
230
|
-
|
-
|
134
|
-
|
-
|
96
|
-
|
-
|
-
|
-
|
-
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Zejula
|
229
|
-
|
-
|
134
|
-
|
-
|
95
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established Pharmaceuticals
|
8,776
|
(7)
|
(8)
|
1,987
|
(22)
|
(24)
|
2,044
|
(8)
|
(8)
|
4,745
|
1
|
1
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Established Respiratory
|
3,900
|
(10)
|
(11)
|
1,415
|
(21)
|
(23)
|
807
|
(13)
|
(12)
|
1,678
|
4
|
3
|
|
Seretide/Advair
|
1,730
|
(29)
|
(29)
|
502
|
(54)
|
(56)
|
502
|
(16)
|
(16)
|
726
|
-
|
(1)
|
|
Flixotide/Flovent
|
629
|
6
|
4
|
368
|
11
|
6
|
88
|
(5)
|
(4)
|
173
|
2
|
2
|
|
Ventolin
|
938
|
27
|
25
|
547
|
55
|
49
|
120
|
(8)
|
(7)
|
271
|
6
|
7
|
|
Avamys/Veramyst
|
324
|
8
|
6
|
(2)
|
>(100)
|
>(100)
|
69
|
(7)
|
(5)
|
257
|
14
|
11
|
|
Other
|
279
|
6
|
2
|
-
|
-
|
-
|
28
|
-
|
(4)
|
251
|
7
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
445
|
2
|
3
|
3
|
-
|
-
|
159
|
(1)
|
(1)
|
283
|
4
|
6
|
|
Augmentin
|
602
|
6
|
6
|
-
|
-
|
-
|
172
|
(5)
|
(4)
|
430
|
11
|
11
|
|
Avodart
|
574
|
-
|
(1)
|
4
|
(67)
|
(67)
|
208
|
(13)
|
(12)
|
362
|
13
|
11
|
|
Imigran/Imitrex
|
138
|
(2)
|
(3)
|
59
|
2
|
-
|
52
|
(9)
|
(7)
|
27
|
4
|
-
|
|
Lamictal
|
566
|
(8)
|
(10)
|
284
|
(8)
|
(12)
|
112
|
(1)
|
-
|
170
|
(12)
|
(13)
|
|
Seroxat/Paxil
|
160
|
(6)
|
(6)
|
-
|
-
|
-
|
37
|
(5)
|
(5)
|
123
|
(6)
|
(7)
|
|
Valtrex
|
107
|
(13)
|
(15)
|
14
|
(33)
|
(38)
|
31
|
3
|
3
|
62
|
(14)
|
(15)
|
|
Other
|
2,284
|
(9)
|
(9)
|
208
|
(40)
|
(43)
|
466
|
(5)
|
(4)
|
1,610
|
(4)
|
(4)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Pharmaceuticals
|
17,554
|
2
|
-
|
7,402
|
(1)
|
(4)
|
4,125
|
1
|
2
|
6,027
|
5
|
4
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals turnover – three months ended 31 December
2019
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
892
|
8
|
9
|
521
|
-
|
1
|
214
|
20
|
22
|
157
|
23
|
22
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Ellipta
products
|
674
|
3
|
4
|
389
|
(6)
|
(5)
|
158
|
17
|
19
|
127
|
20
|
19
|
|
Anoro Ellipta
|
141
|
(2)
|
(1)
|
91
|
(7)
|
(6)
|
33
|
14
|
17
|
17
|
-
|
-
|
|
Arnuity Ellipta
|
15
|
15
|
15
|
13
|
18
|
18
|
-
|
-
|
-
|
2
|
-
|
-
|
|
Incruse Ellipta
|
77
|
(11)
|
(10)
|
52
|
(13)
|
(12)
|
18
|
(10)
|
(10)
|
7
|
-
|
-
|
|
Relvar/Breo Ellipta
|
269
|
(19)
|
(19)
|
107
|
(42)
|
(41)
|
74
|
4
|
6
|
88
|
16
|
14
|
|
Trelegy Ellipta
|
172
|
>100
|
>100
|
126
|
>100
|
>100
|
33
|
>100
|
>100
|
13
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala
|
218
|
26
|
28
|
132
|
23
|
24
|
56
|
27
|
32
|
30
|
36
|
36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,257
|
(1)
|
-
|
782
|
(1)
|
1
|
296
|
(7)
|
(4)
|
179
|
3
|
5
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Dolutegravir
products
|
1,208
|
-
|
2
|
768
|
-
|
2
|
278
|
(4)
|
(1)
|
162
|
9
|
11
|
|
Tivicay
|
426
|
(6)
|
(4)
|
244
|
(13)
|
(11)
|
100
|
(4)
|
(1)
|
82
|
22
|
22
|
|
Triumeq
|
638
|
(8)
|
(5)
|
408
|
(5)
|
(3)
|
153
|
(16)
|
(13)
|
77
|
(4)
|
-
|
|
Juluca
|
111
|
79
|
79
|
89
|
59
|
59
|
19
|
>100
|
>100
|
3
|
>100
|
100
|
|
Dovato
|
33
|
-
|
-
|
27
|
-
|
-
|
6
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
15
|
(50)
|
(47)
|
-
|
-
|
-
|
5
|
(55)
|
(55)
|
10
|
(33)
|
(27)
|
|
Selzentry
|
23
|
(26)
|
(23)
|
13
|
(19)
|
(19)
|
7
|
(22)
|
(11)
|
3
|
(50)
|
(50)
|
|
Other
|
11
|
10
|
-
|
1
|
>100
|
>100
|
6
|
-
|
(17)
|
4
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno- inflammation
|
170
|
25
|
26
|
148
|
22
|
25
|
12
|
20
|
20
|
10
|
>100
|
60
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Benlysta
|
170
|
23
|
24
|
148
|
22
|
25
|
12
|
20
|
20
|
10
|
43
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
66
|
-
|
-
|
37
|
-
|
-
|
29
|
-
|
-
|
-
|
-
|
-
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Zejula
|
66
|
-
|
-
|
37
|
-
|
-
|
29
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established Pharmaceuticals
|
2,173
|
(15)
|
(14)
|
470
|
(32)
|
(31)
|
497
|
(18)
|
(15)
|
1,206
|
(5)
|
(4)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Established Respiratory
|
965
|
(17)
|
(16)
|
341
|
(32)
|
(31)
|
196
|
(17)
|
(15)
|
428
|
1
|
1
|
|
Seretide/Advair
|
414
|
(36)
|
(35)
|
104
|
(65)
|
(64)
|
119
|
(21)
|
(18)
|
191
|
(4)
|
(4)
|
|
Flixotide/Flovent
|
186
|
12
|
13
|
115
|
22
|
22
|
22
|
(15)
|
(12)
|
49
|
7
|
9
|
|
Ventolin
|
226
|
5
|
8
|
124
|
13
|
16
|
31
|
(14)
|
(11)
|
71
|
3
|
4
|
|
Avamys/Veramyst
|
72
|
(1)
|
-
|
(2)
|
>(100)
|
>(100)
|
15
|
(12)
|
(6)
|
59
|
5
|
5
|
|
Other
Respiratory
|
67
|
6
|
3
|
-
|
-
|
-
|
9
|
29
|
-
|
58
|
4
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
112
|
(3)
|
1
|
-
|
-
|
-
|
40
|
(7)
|
(5)
|
72
|
1
|
6
|
|
Augmentin
|
158
|
8
|
11
|
-
|
-
|
-
|
47
|
(4)
|
(2)
|
111
|
14
|
18
|
|
Avodart
|
140
|
(6)
|
(5)
|
-
|
-
|
-
|
48
|
(20)
|
(15)
|
92
|
7
|
6
|
|
Imigran/Imitrex
|
35
|
(12)
|
(10)
|
15
|
(21)
|
(16)
|
13
|
(7)
|
-
|
7
|
-
|
(14)
|
|
Lamictal
|
145
|
(9)
|
(8)
|
73
|
(12)
|
(11)
|
28
|
(7)
|
-
|
44
|
(4)
|
(9)
|
|
Seroxat/Paxil
|
38
|
(17)
|
(15)
|
-
|
-
|
-
|
9
|
(10)
|
(10)
|
29
|
(19)
|
(17)
|
|
Valtrex
|
27
|
(18)
|
(18)
|
4
|
(43)
|
(43)
|
8
|
14
|
14
|
15
|
(21)
|
(21)
|
|
Other
|
553
|
(23)
|
(20)
|
37
|
(51)
|
(54)
|
108
|
(30)
|
(29)
|
408
|
(16)
|
(12)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Pharmaceuticals
|
4,558
|
(5)
|
(4)
|
1,958
|
(8)
|
(6)
|
1,048
|
(6)
|
(3)
|
1,552
|
(2)
|
-
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – year ended 31 December 2019
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
1,018
|
16
|
15
|
430
|
15
|
10
|
343
|
2
|
3
|
245
|
43
|
50
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Bexsero
|
679
|
16
|
16
|
260
|
30
|
25
|
319
|
3
|
4
|
100
|
37
|
48
|
|
Menveo
|
267
|
15
|
13
|
170
|
(2)
|
(6)
|
18
|
6
|
6
|
79
|
93
|
100
|
|
Other
|
72
|
11
|
11
|
-
|
-
|
-
|
6
|
(25)
|
(25)
|
66
|
16
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
541
|
3
|
1
|
412
|
7
|
3
|
56
|
(15)
|
(15)
|
73
|
1
|
4
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Fluarix, FluLaval
|
541
|
3
|
1
|
412
|
7
|
3
|
56
|
(15)
|
(15)
|
73
|
1
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
1,810
|
>100
|
>100
|
1,669
|
>100
|
>100
|
54
|
>100
|
>100
|
87
|
78
|
76
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Shingrix
|
1,810
|
>100
|
>100
|
1,669
|
>100
|
>100
|
54
|
>100
|
>100
|
87
|
78
|
76
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established Vaccines
|
3,788
|
2
|
1
|
1,394
|
15
|
11
|
1,035
|
(11)
|
(10)
|
1,359
|
1
|
2
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Infanrix, Pediarix
|
733
|
8
|
6
|
360
|
22
|
17
|
213
|
(20)
|
(19)
|
160
|
36
|
35
|
|
Boostrix
|
584
|
13
|
11
|
299
|
13
|
9
|
156
|
(4)
|
(3)
|
129
|
43
|
44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
|
874
|
8
|
6
|
529
|
16
|
11
|
231
|
(6)
|
(5)
|
114
|
9
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotarix
|
558
|
7
|
6
|
140
|
11
|
6
|
112
|
2
|
3
|
306
|
7
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synflorix
|
468
|
10
|
11
|
-
|
-
|
-
|
54
|
(7)
|
(5)
|
414
|
13
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Priorix, Priorix Tetra,
Varilrix
|
232
|
(24)
|
(23)
|
-
|
-
|
-
|
100
|
(37)
|
(37)
|
132
|
(9)
|
(9)
|
|
Cervarix
|
50
|
(64)
|
(64)
|
-
|
-
|
-
|
21
|
5
|
5
|
29
|
(75)
|
(76)
|
|
Other
|
289
|
(8)
|
(7)
|
66
|
3
|
2
|
148
|
8
|
10
|
75
|
(33)
|
(33)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Vaccines
|
7,157
|
21
|
19
|
3,905
|
45
|
39
|
1,488
|
(5)
|
(4)
|
1,764
|
8
|
9
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – three months ended 31 December
2019
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
–––––––––––––––––––––––––––––––––––––––
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
|
––––––––––––––––––––––––
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
203
|
8
|
14
|
25
|
(50)
|
(36)
|
83
|
6
|
9
|
95
|
58
|
62
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Bexsero
|
112
|
(2)
|
5
|
12
|
(48)
|
(26)
|
76
|
6
|
8
|
24
|
26
|
32
|
|
Menveo
|
66
|
50
|
57
|
13
|
(52)
|
(44)
|
6
|
50
|
50
|
47
|
>100
|
>100
|
|
Other
|
25
|
(17)
|
(17)
|
-
|
-
|
-
|
1
|
(50)
|
(50)
|
24
|
(14)
|
(14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
138
|
(28)
|
(26)
|
92
|
(32)
|
(30)
|
22
|
(29)
|
(29)
|
24
|
(11)
|
(4)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Fluarix, FluLaval
|
138
|
(28)
|
(26)
|
92
|
(32)
|
(30)
|
22
|
(29)
|
(29)
|
24
|
(11)
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
532
|
>100
|
>100
|
494
|
>100
|
>100
|
19
|
>100
|
>100
|
19
|
27
|
40
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Shingrix
|
532
|
>100
|
>100
|
494
|
>100
|
>100
|
19
|
>100
|
>100
|
19
|
27
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established Vaccines
|
869
|
(1)
|
2
|
298
|
8
|
12
|
226
|
(15)
|
(12)
|
345
|
3
|
5
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Infanrix, Pediarix
|
156
|
(5)
|
(2)
|
68
|
(9)
|
(7)
|
44
|
(27)
|
(23)
|
44
|
47
|
50
|
|
Boostrix
|
130
|
(6)
|
(4)
|
66
|
3
|
6
|
34
|
(8)
|
(5)
|
30
|
(21)
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
|
195
|
3
|
6
|
111
|
8
|
11
|
53
|
(12)
|
(8)
|
31
|
15
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotarix
|
141
|
5
|
8
|
34
|
36
|
36
|
28
|
-
|
-
|
79
|
(2)
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synflorix
|
124
|
17
|
20
|
-
|
-
|
-
|
10
|
(52)
|
(48)
|
114
|
34
|
36
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Priorix, Priorix Tetra,
Varilrix
|
70
|
10
|
11
|
-
|
-
|
-
|
26
|
(20)
|
(20)
|
44
|
40
|
43
|
|
Cervarix
|
(13)
|
>(100)
|
>(100)
|
-
|
-
|
-
|
5
|
-
|
-
|
(18)
|
>(100)
|
>(100)
|
|
Other
|
66
|
3
|
9
|
19
|
>100
|
>100
|
26
|
10
|
23
|
21
|
(33)
|
(43)
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
Vaccines
|
1,742
|
18
|
21
|
909
|
36
|
40
|
350
|
(7)
|
(4)
|
483
|
11
|
14
|
|
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
–––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance sheet
|
|
|
|
|
31 December 2019
£m
|
|
31
December 2018
£m
|
|
ASSETS
|
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
|
Property,
plant and equipment
|
|
|
10,348
|
|
11,058
|
|
Right
of use assets
|
|
|
966
|
|
-
|
|
Goodwill
|
|
|
10,562
|
|
5,789
|
|
Other
intangible assets
|
|
|
30,955
|
|
17,202
|
|
Investments
in associates and joint ventures
|
|
|
314
|
|
236
|
|
Other
investments
|
|
|
1,837
|
|
1,322
|
|
Deferred
tax assets
|
|
|
4,096
|
|
3,887
|
|
Derivative
financial instruments
|
|
|
103
|
|
69
|
|
Other
non-current assets
|
|
|
1,020
|
|
1,576
|
|
|
|
|
|
|
|
|
Total non-current assets
|
|
|
60,201
|
|
41,139
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Inventories
|
|
|
5,947
|
|
5,476
|
|
Current
tax recoverable
|
|
|
262
|
|
229
|
|
Trade
and other receivables
|
|
|
7,202
|
|
6,423
|
|
Derivative
financial instruments
|
|
|
421
|
|
188
|
|
Liquid
investments
|
|
|
79
|
|
84
|
|
Cash
and cash equivalents
|
|
|
4,707
|
|
3,874
|
|
Assets
held for sale
|
|
|
873
|
|
653
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
19,491
|
|
16,927
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
79,692
|
|
58,066
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
Short-term
borrowings
|
|
|
(6,918)
|
|
(5,793)
|
|
Contingent
consideration liabilities
|
|
|
(755)
|
|
(837)
|
|
Trade
and other payables
|
|
|
(14,939)
|
|
(14,037)
|
|
Derivative
financial instruments
|
|
|
(188)
|
|
(127)
|
|
Current
tax payable
|
|
|
(629)
|
|
(965)
|
|
Short-term
provisions
|
|
|
(621)
|
|
(732)
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
(24,050)
|
|
(22,491)
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
Long-term
borrowings
|
|
|
(23,590)
|
|
(20,271)
|
|
Corporation
tax payable
|
|
|
(189)
|
|
(272)
|
|
Deferred
tax liabilities
|
|
|
(3,810)
|
|
(1,156)
|
|
Pensions
and other post-employment benefits
|
|
|
(3,457)
|
|
(3,125)
|
|
Other
provisions
|
|
|
(670)
|
|
(691)
|
|
Derivative
financial instruments
|
|
|
(1)
|
|
(1)
|
|
Contingent
consideration liabilities
|
|
|
(4,724)
|
|
(5,449)
|
|
Other
non-current liabilities
|
|
|
(844)
|
|
(938)
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
(37,285)
|
|
(31,903)
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
|
|
(61,335)
|
|
(54,394)
|
|
|
|
|
|
|
|
|
NET ASSETS
|
|
|
18,357
|
|
3,672
|
|
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
|
Share
capital
|
|
|
1,346
|
|
1,345
|
|
Share
premium account
|
|
|
3,174
|
|
3,091
|
|
Retained
earnings
|
|
|
5,109
|
|
(2,137)
|
|
Other
reserves
|
|
|
2,355
|
|
2,061
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
11,984
|
|
4,360
|
|
|
|
|
|
|
|
|
Non-controlling
interests
|
|
|
6,373
|
|
(688)
|
|
|
|
|
|
|
|
|
TOTAL EQUITY
|
|
|
18,357
|
|
3,672
|
|
|
|
|
|
|
|
|
Statement of changes in equity
|
|
|
Share
capital
£m
|
Share
premium
£m
|
Retained
earnings
£m
|
Other
reserves
£m
|
Share-
holder’s
equity
£m
|
Non-
controlling
interests
£m
|
Total
equity
£m
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
As
previously reported
|
1,345
|
3,091
|
(2,137)
|
2,061
|
4,360
|
(688)
|
3,672
|
|
Implementation
of IFRS 16
|
-
|
-
|
(93)
|
-
|
(93)
|
-
|
(93)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 1
January 2019, as adjusted
|
1,345
|
3,091
|
(2,230)
|
2,061
|
4,267
|
(688)
|
3,579
|
|
Profit for the
period
|
|
|
4,645
|
|
4,645
|
623
|
5,268
|
|
Other comprehensive
(expense)/income for the
period
|
|
|
(1,766)
|
274
|
(1,492)
|
(75)
|
(1,567)
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Total
comprehensive income/(expense) for the
period
|
|
|
2,879
|
274
|
3,153
|
548
|
3,701
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
(364)
|
(364)
|
|
Changes
to non-controlling interests
|
|
|
|
|
|
(10)
|
(10)
|
|
Dividends
to shareholders
|
|
|
(3,953)
|
|
(3,953)
|
|
(3,953)
|
|
Recognition
of interest in Consumer
Healthcare
Joint Venture
|
|
|
8,082
|
|
8,082
|
6,887
|
14,969
|
|
Shares
issued
|
1
|
50
|
|
|
51
|
|
51
|
|
Realised
after tax losses on disposal of equity
investments
|
|
|
(4)
|
4
|
|
|
-
|
|
Shares
acquired by ESOP Trusts
|
|
33
|
295
|
(328)
|
|
|
-
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
(344)
|
344
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
365
|
|
365
|
|
365
|
|
Tax on
share-based incentive plans
|
|
|
19
|
|
19
|
|
19
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 31 December 2019
|
1,346
|
3,174
|
5,109
|
2,355
|
11,984
|
6,373
|
18,357
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As
previously reported
|
1,343
|
3,019
|
(6,477)
|
2,047
|
(68)
|
3,557
|
3,489
|
|
Implementation
of IFRS 15
|
|
|
(4)
|
|
(4)
|
|
(4)
|
|
Implementation
of IFRS 9
|
|
|
277
|
(288)
|
(11)
|
|
(11)
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 1
January 2018, as adjusted
|
1,343
|
3,019
|
(6,204)
|
1,759
|
(83)
|
3,557
|
3,474
|
|
Profit
for the period
|
|
|
3,623
|
|
3,623
|
423
|
4,046
|
|
Other comprehensive
income/(expense) for the
period
|
|
|
124
|
131
|
255
|
(1)
|
254
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Total
comprehensive income for the period
|
|
|
3,747
|
131
|
3,878
|
422
|
4,300
|
|
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
(570)
|
(570)
|
|
Contributions
from non-controlling interests
|
|
|
|
|
|
21
|
21
|
|
Derecognition
of non-controlling interests
in
Consumer Healthcare Joint Venture
|
|
|
4,056
|
|
4,056
|
(4,118)
|
(62)
|
|
Dividends
to shareholders
|
|
|
(3,927)
|
|
(3,927)
|
|
(3,927)
|
|
Shares
issued
|
2
|
72
|
|
|
74
|
|
74
|
|
Realised
after tax profits on disposal of equity
investments
|
|
|
56
|
(56)
|
|
|
-
|
|
Share
of associates and joint ventures
realised
profits on disposal of equity
investments
|
|
|
38
|
(38)
|
|
|
-
|
|
Write-down
on shares held by ESOP Trusts
|
|
|
(265)
|
265
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
360
|
|
360
|
|
360
|
|
Tax on
share-based incentive plans
|
|
|
2
|
|
2
|
|
2
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
At 31
December 2018
|
1,345
|
3,091
|
(2,137)
|
2,061
|
4,360
|
(688)
|
3,672
|
|
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
––––––––––––
|
|
Cash flow statement – year ended 31 December
2019
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
|
|
Profit after tax
|
5,268
|
|
4,046
|
|
|
Tax on
profits
|
953
|
|
754
|
|
|
Share
of after tax profits of associates and joint ventures
|
(74)
|
|
(31)
|
|
|
Profit
on disposal of interest in associates
|
-
|
|
(3)
|
|
|
Net
finance expense
|
814
|
|
717
|
|
|
Depreciation,
amortisation and other adjusting items
|
2,996
|
|
1,763
|
|
|
Decrease/(increase)
in working capital
|
531
|
|
(247)
|
|
|
Contingent
consideration paid
|
(780)
|
|
(984)
|
|
|
(Decrease)/increase
in other net liabilities (excluding contingent
consideration
paid)
|
(176)
|
|
3,732
|
|
|
|
|
|
|
|
|
Cash generated from operations
|
9,532
|
|
9,747
|
|
|
Taxation
paid
|
(1,512)
|
|
(1,326)
|
|
|
|
|
|
|
|
|
Net cash inflow from operating activities
|
8,020
|
|
8,421
|
|
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
|
Purchase
of property, plant and equipment
|
(1,265)
|
|
(1,344)
|
|
|
Proceeds
from sale of property, plant and equipment
|
95
|
|
168
|
|
|
Purchase
of intangible assets
|
(898)
|
|
(452)
|
|
|
Proceeds
from sale of intangible assets
|
404
|
|
256
|
|
|
Purchase
of equity investments
|
(258)
|
|
(309)
|
|
|
Proceeds
from sale of equity investments
|
69
|
|
151
|
|
|
Purchase
of businesses, net of cash acquired
|
(3,571)
|
|
-
|
|
|
Contingent
consideration paid
|
(113)
|
|
(153)
|
|
|
Disposal
of businesses
|
104
|
|
26
|
|
|
Proceeds
from disposal of interest in associates
|
-
|
|
3
|
|
|
Investment
in associates and joint ventures
|
(11)
|
|
(10)
|
|
|
Interest
received
|
82
|
|
72
|
|
|
Decrease
in liquid investments
|
1
|
|
-
|
|
|
Dividends
from associates and joint ventures
|
7
|
|
39
|
|
|
|
|
|
|
|
|
Net cash outflow from investing activities
|
(5,354)
|
|
(1,553)
|
|
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
|
Issue
of share capital
|
51
|
|
74
|
|
|
Increase
in short-term loans
|
6,963
|
|
81
|
|
|
Increase
in long-term loans
|
4,794
|
|
10,138
|
|
|
Repayment
of short-term loans
|
(8,028)
|
|
(2,067)
|
|
|
Repayment
of lease liabilities
|
(214)
|
|
(28)
|
|
|
Purchase
of non-controlling interests
|
(7)
|
|
(9,320)
|
|
|
Interest
paid
|
(895)
|
|
(766)
|
|
|
Dividends
paid to shareholders
|
(3,953)
|
|
(3,927)
|
|
|
Distributions
to non-controlling interests
|
(364)
|
|
(570)
|
|
|
Contributions
from non-controlling interests
|
-
|
|
21
|
|
|
Other
financing items
|
(187)
|
|
(25)
|
|
|
|
|
|
|
|
|
Net cash outflow from financing activities
|
(1,840)
|
|
(6,389)
|
|
|
|
|
|
|
|
|
Increase in cash and bank overdrafts in the year
|
826
|
|
479
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the year
|
4,087
|
|
3,600
|
|
|
Exchange
adjustments
|
(82)
|
|
8
|
|
|
Increase
in cash and bank overdrafts
|
826
|
|
479
|
|
|
|
|
|
|
|
|
Cash and bank overdrafts at end of the year
|
4,831
|
|
4,087
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at end of the year comprise:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
4,707
|
|
3,874
|
|
|
Cash
and cash equivalents reported in assets held for sale
|
507
|
|
485
|
|
|
|
|
|
|
|
|
|
5,214
|
|
4,359
|
|
|
Overdrafts
|
(383)
|
|
(272)
|
|
|
|
|
|
|
|
|
4,831
|
|
4,087
|
|
|
|
|
|
|
|
|
Segment information
|
|
|
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the
Corporate Executive Team (CET). GSK reports results under four
segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and
Consumer Healthcare, and individual members of the CET are
responsible for each segment.
The
Pharmaceuticals R&D segment is the responsibility of the Chief
Scientific Officer and President, R&D and is reported as a
separate segment. The operating profit of this segment excludes the
ViiV Healthcare operating profit (including R&D expenditure)
that is reported within the Pharmaceuticals segment.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
Corporate
and other unallocated turnover and costs include the results of
certain Consumer Healthcare products which are being held for sale
in a number of markets in order to meet anti-trust approval
requirements, together with the costs of corporate
functions.
|
|
Turnover by segment
|
|
|
2019
£m
|
|
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
17,554
|
|
17,269
|
|
2
|
|
-
|
|
Vaccines
|
7,157
|
|
5,894
|
|
21
|
|
19
|
|
Consumer
Healthcare
|
8,995
|
|
7,658
|
|
17
|
|
17
|
|
|
|
|
|
|
|
|
|
|
|
33,706
|
|
30,821
|
|
9
|
|
8
|
|
Corporate
and other unallocated turnover
|
48
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
turnover
|
33,754
|
|
30,821
|
|
10
|
|
8
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
2019
£m
|
|
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
7,964
|
|
8,420
|
|
(5)
|
|
(8)
|
|
Pharmaceuticals
R&D
|
(3,369)
|
|
(2,676)
|
|
26
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
including R&D
|
4,595
|
|
5,744
|
|
(20)
|
|
(22)
|
|
Vaccines
|
2,966
|
|
1,943
|
|
53
|
|
46
|
|
Consumer
Healthcare
|
1,874
|
|
1,517
|
|
24
|
|
22
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
9,435
|
|
9,204
|
|
3
|
|
-
|
|
Corporate
and other unallocated costs
|
(463)
|
|
(459)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
8,972
|
|
8,745
|
|
3
|
|
-
|
|
Adjusting
items
|
(2,011)
|
|
(3,262)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
6,961
|
|
5,483
|
|
27
|
|
23
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
98
|
|
81
|
|
|
|
|
|
Finance
costs
|
(912)
|
|
(798)
|
|
|
|
|
|
Profit
on disposal of associates
|
-
|
|
3
|
|
|
|
|
|
Share
of after tax profits of
associates
and joint ventures
|
74
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
6,221
|
|
4,800
|
|
30
|
|
25
|
|
|
|
|
|
|
|
|
|
|
Turnover by segment
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
4,558
|
|
4,810
|
|
(5)
|
|
(4)
|
|
Vaccines
|
1,742
|
|
1,479
|
|
18
|
|
21
|
|
Consumer
Healthcare
|
2,571
|
|
1,908
|
|
35
|
|
37
|
|
|
|
|
|
|
|
|
|
|
|
8,871
|
|
8,197
|
|
8
|
|
10
|
|
Corporate
and other unallocated turnover
|
28
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
turnover
|
8,899
|
|
8,197
|
|
9
|
|
11
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
Q4 2019
£m
|
|
Q4
2018
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
|
1,935
|
|
2,340
|
|
(17)
|
|
(15)
|
|
Pharmaceuticals
R&D
|
(927)
|
|
(778)
|
|
19
|
|
21
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals
including R&D
|
1,008
|
|
1,562
|
|
(35)
|
|
(33)
|
|
Vaccines
|
578
|
|
420
|
|
38
|
|
42
|
|
Consumer
Healthcare
|
440
|
|
352
|
|
25
|
|
33
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,026
|
|
2,334
|
|
(13)
|
|
(10)
|
|
Corporate
and other unallocated costs
|
(174)
|
|
(138)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
1,852
|
|
2,196
|
|
(16)
|
|
(11)
|
|
Adjusting
items
|
50
|
|
(642)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
1,902
|
|
1,554
|
|
22
|
|
29
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
11
|
|
24
|
|
|
|
|
|
Finance
costs
|
(206)
|
|
(209)
|
|
|
|
|
|
Share
of after tax profits of associates
and
joint ventures
|
4
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
1,711
|
|
1,374
|
|
25
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Legal matters
The Group is involved in significant legal and
administrative proceedings, principally product liability,
intellectual property, tax, anti-trust, consumer fraud and
governmental investigations, which are more fully described in the
‘Legal Proceedings’ note in the Annual Report 2018. At
31 December 2019, the Group’s aggregate provision for legal
and other disputes (not including tax matters described on page 19)
was £0.2 billion (31 December 2018: £0.2 billion). The
Group may become involved in significant legal proceedings in
respect of which it is not possible to make a reliable estimate of
the expected financial effect, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
Three
significant developments since the date of the Annual Report 2018
are as follows:
In
November 2019, the Group reached a
settlement with respect to the claims brought by 38 health
insurance companies against the Group, relating to reimbursements
the insurers made for 17 medicines manufactured at the
Group’s former Cidra plant in Puerto Rico between 2000 and
2006. Accordingly, the trial of
the matter scheduled in US federal court for 12 November did not
take place and the matter is now concluded.
The Group has been contacted by several regulatory authorities
regarding the detection of genotoxic nitrosamine (NDMA) in
Zantac
(ranitidine) products. Based on the
information received to date and correspondence with regulators,
the Group made the decision in September 2019 to suspend the
release, distribution and supply of all dose forms of
Zantac
to all markets pending the outcome of
the ongoing tests and investigations. Also, as a precautionary
action, in early October 2019, the Group made the decision to
initiate a voluntary recall (pharmacy/retail level recall) of
all Zantac products globally. The Group is continuing with
investigations into the potential source of NDMA. The first
Zantac
personal injury claim was filed on 15
October 2019 against GSK and several other pharmaceutical companies
in federal court in the Eastern District of California. Since that
time, additional cases have been filed in the US naming GSK as a
defendant.
On 12
February 2016, the UK Competition and Markets Authority (CMA)
issued a decision fining the Group £37.6 million for
infringement of the Competition Act in connection with agreements
to settle patent disputes the Group entered into between 2001 and
2002 with potential suppliers of generic paroxetine formulations.
The Group appealed to the Competition Appeal Tribunal (CAT), which
delivered its initial judgement upholding the fine on 8 March 2018
but referred certain questions of law to the European Union Court
of Justice (“ECJ”). On 30 January 2020, the ECJ issued
its judgement endorsing the criteria used by the CMA in levying the
fine and the matter now will return to the CAT for entry of a final
judgement.
The ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
|
|
Additional information
|
|
Accounting policies and basis of preparation
|
|
This
unaudited Results Announcement contains condensed financial
information for the year-end and three months ended 31 December 2019, and should be read in
conjunction with the Annual Report 2018, which was prepared
in accordance with International Financial Reporting Standards as
adopted by the European Union. This Results Announcement has been
prepared applying consistent accounting policies to those applied
by the Group in the Annual Report 2018, except for the
implementation of IFRS 16 ‘Leases’ from 1 January
2019.
IFRS 16
‘Leases’ was implemented by the Group from 1 January
2019. The new standard replaces IAS 17 ‘Leases’ and
requires lease liabilities and right of use assets to be recognised
on the balance sheet for almost all leases. GSK has applied the
modified transition approach on adoption with no restatement of
comparative information. The adjustment made on the transition date
of 1 January 2019 to each balance sheet line item is as
follows:
|
|
|
31
December 2018
as
previously
reported
£m
|
|
IFRS
16
adjustments
£m
|
|
1
January 2019
as
adjusted
£m
|
|
|
|
|
|
|
|
|
Property,
plant and equipment
|
11,058
|
|
(98)
|
|
10,960
|
|
Right
of use assets
|
-
|
|
1,071
|
|
1,071
|
|
Other
non-current assets
|
1,576
|
|
(11)
|
|
1,565
|
|
Trade
and other receivables
|
6,423
|
|
3
|
|
6,426
|
|
Deferred
tax assets
|
3,887
|
|
39
|
|
3,926
|
|
Short-term
borrowings
|
(5,793)
|
|
(229)
|
|
(6,022)
|
|
Long-term
borrowings
|
(20,271)
|
|
(1,074)
|
|
(21,345)
|
|
Trade
and other payables
|
(14,037)
|
|
10
|
|
(14,027)
|
|
Current
and non-current provisions
|
(1,423)
|
|
35
|
|
(1,388)
|
|
Other
non-current liabilities
|
(938)
|
|
160
|
|
(778)
|
|
Deferred
tax liabilities
|
(1,156)
|
|
1
|
|
(1,155)
|
|
|
|
|
|
|
|
|
Total
effect on net assets
|
3,672
|
|
(93)
|
|
3,579
|
|
|
|
|
|
|
|
|
Retained
earnings
|
(2,137)
|
|
(93)
|
|
(2,230)
|
|
|
|
|
|
|
|
|
Total
effect on equity
|
3,672
|
|
(93)
|
|
3,579
|
|
|
|
|
|
|
|
|
The new
Standard has not had a material impact on the Group’s Income
statement or Cash flow statement.
|
|
The
Group assesses whether a contract is or contains a lease at
inception of the contract. The Group recognises a right of use asset and a
corresponding lease liability with respect to all lease
arrangements in which it is the lessee, except for
short‑term
leases (defined as leases with a lease term of 12 months or less)
and leases of low value assets. For these leases, the Group
recognises the lease payments as an operating expense on a
straight‑line basis over the
term of the lease. The lease liability is initially measured at the
present value of the lease payments that are not paid at the
commencement date. The discount rate applied is the rate implicit
in the lease. If this rate cannot be readily determined, the Group
uses its incremental borrowing rate.
The
lease liability is subsequently measured by increasing the carrying
amount to reflect interest on the lease liability (using the
effective interest method) and by reducing the carrying amount to
reflect the lease payments made.
The
right of use assets primarily
comprise property and reflect the initial measurement of the
corresponding lease liability, lease payments made at or before the
commencement day and any initial direct costs. They are
subsequently measured at cost less accumulated depreciation and
impairment losses.
|
|
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2018 were published
in the Annual Report 2018, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditors was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
|
|
Exchange rates
|
|
GSK
operates in many countries, and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
|
|
2019
|
|
2018
|
|
Q4 2019
|
|
Q4
2018
|
||
|
|
|
|
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
|
1.28
|
|
1.33
|
|
1.30
|
|
1.27
|
|
|
|
Euro/£
|
|
|
1.14
|
|
1.13
|
|
1.17
|
|
1.13
|
|
|
|
Yen/£
|
|
|
139
|
|
147
|
|
141
|
|
144
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
|
|
|
|
||
|
|
|
US$/£
|
|
|
1.32
|
|
1.27
|
|
1.32
|
|
1.27
|
|
|
|
Euro/£
|
|
|
1.18
|
|
1.11
|
|
1.18
|
|
1.11
|
|
|
|
Yen/£
|
|
|
143
|
|
140
|
|
143
|
|
140
|
|
During Q4 2019 average Sterling exchange rates were stronger
against the US Dollar and Euro but weaker against the Yen compared
with the same period in 2018. During the year ended 31 December
2019, average Sterling exchange rates were weaker against the US
Dollar and the Yen but stronger against the Euro. Period-end
Sterling exchange rates were stronger against the US Dollar, the
Euro and Yen compared with the 2018 period-end rates.
|
|
Net assets
|
|
The
book value of net assets increased by £14,685 million from
£3,672 million at 31 December 2018 to £18,357 million at
31 December 2019. This primarily reflected the acquisition of the
Pfizer consumer healthcare business, partly offset by the
re-measurement losses on defined benefit plans during the
year.
The
carrying value of investments in associates and joint ventures at
31 December 2019 was £314 million (31 December 2018: £236
million), with a market value of £396 million (31 December
2018: £487 million).
At 31
December 2019, the net deficit on the Group’s pension plans
was £1,921 million compared with £995 million at 31
December 2018. The increase in the net deficit primarily arose from
decreases in the rates used to discount UK pension liabilities from
2.9% to 2.0%, and US pension liabilities from 4.2% to 3.2%, partly
offset by higher UK assets and a reduction in the UK inflation rate
from 3.2% to 3.0%.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £1,011 million (31
December 2018: £1,240 million).
|
|
The
contingent consideration liability amounted to £5,479 million
at 31 December 2019 (31 December 2018: £6,286 million), of
which £5,103 million (31 December 2018: £5,937 million)
represented the estimated present value of amounts payable to
Shionogi relating to ViiV Healthcare and £339 million (31
December 2018: £296 million) represented the estimated present
value of contingent consideration payable to Novartis related to
the Vaccines acquisition.
Of the contingent consideration payable (on a post-tax basis) to
Shionogi at 31 December 2019, £730 million (31 December 2018:
£815 million) is expected to be paid within one
year.
|
|
Movements in contingent consideration were as follows:
|
|
2019
|
ViiV Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,937
|
|
6,286
|
|
Additions
|
-
|
|
4
|
|
Re-measurement
through income statement
|
31
|
|
82
|
|
Cash
payments: operating cash flows
|
(767)
|
|
(780)
|
|
Cash
payments: investing activities
|
(98)
|
|
(113)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,103
|
|
5,479
|
|
|
|
|
|
|
2018
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,542
|
|
6,172
|
|
Re-measurement
through income statement
|
1,188
|
|
1,251
|
|
Cash
payments: operating cash flows
|
(703)
|
|
(984)
|
|
Cash
payments: investing activities
|
(90)
|
|
(153)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,937
|
|
6,286
|
|
|
|
|
|
|
The
liabilities for the Pfizer put option and the contingent
consideration at 31 December 2019 have been calculated based on the
period-end exchange rates, primarily US$1.32/£1 and
€1.18/£1. Sensitivity analyses for the Pfizer put option
and each of the largest contingent consideration liabilities are
set out below.
|
|
Increase/(decrease) in liability
|
ViiV
Healthcare
put
option
|
|
Shionogi-
ViiV
Healthcare
contingent
consideration
|
|
Novartis
Vaccines
contingent
consideration
|
|
|
£m
|
|
£m
|
|
£m
|
|
|
|
|
|
|
|
|
10%
increase in sales forecasts
|
119
|
|
489
|
|
65
|
|
10%
decrease in sales forecasts
|
(118)
|
|
(490)
|
|
(65)
|
|
1% (100
basis points) increase in discount rate
|
(43)
|
|
(192)
|
|
(24)
|
|
1% (100
basis points) decrease in discount rate
|
46
|
|
205
|
|
27
|
|
5%
increase in probability of milestone success
|
|
|
|
|
7
|
|
5%
decrease in probability of milestone success
|
|
|
|
|
(7)
|
|
5 cent
appreciation of US Dollar
|
28
|
|
146
|
|
(4)
|
|
5 cent
depreciation of US Dollar
|
(26)
|
|
(135)
|
|
3
|
|
10 cent
appreciation of US Dollar
|
58
|
|
302
|
|
(8)
|
|
10 cent
depreciation of US Dollar
|
(49)
|
|
(261)
|
|
7
|
|
5 cent
appreciation of Euro
|
18
|
|
49
|
|
12
|
|
5 cent
depreciation of Euro
|
(16)
|
|
(48)
|
|
(11)
|
|
10 cent
appreciation of Euro
|
37
|
|
106
|
|
26
|
|
10 cent
depreciation of Euro
|
(31)
|
|
(91)
|
|
(22)
|
|
|
|
|
|
|
|
|
Contingent liabilities
|
|
There
were contingent liabilities at 31 December 2019 in respect of
guarantees and indemnities entered into as part of the ordinary
course of the Group’s business. No material losses are
expected to arise from such contingent liabilities. Provision is
made for the outcome of legal and tax disputes where it is both
probable that the Group will suffer an outflow of funds and it is
possible to make a reliable estimate of that outflow. Descriptions
of the significant legal disputes to which the Group is a party are
set out on page 54.
|
|
Business acquisitions
|
|
On 22
January 2019, GSK acquired 100% of Tesaro, an oncology focused
biopharmaceutical company, for cash consideration of $5.0 billion
(£3.9 billion) in order to strengthen the Group’s
pharmaceutical pipeline.
Since
22 January 2019, sales of £0.2 billion arising from the Tesaro
business have been included in Group turnover. As the company is
being integrated into the Group’s existing activities, it is
not practicable to identify the impact on Group profit since
acquisition.
On 31
July 2019, GSK and Pfizer contributed their respective Consumer
Healthcare businesses into a new Consumer Healthcare Joint Venture
in a non-cash transaction, whereby GSK acquired Pfizer’s
consumer healthcare business in return for shares in the Joint
Venture. GSK has an equity interest of 68% and majority control of
the Joint Venture and Pfizer has an equity interest of
32%.
The
non-controlling interest in the Consumer Healthcare Joint Venture,
calculated applying the partial goodwill method, represents
Pfizer’s share of the net assets of the Joint
Venture.
The
goodwill in the business acquired from Pfizer represents the
potential for further synergies arising from combining the acquired
business with GSK’s existing business together with the value
of the workforce acquired. The goodwill recognised is not expected
to be deductible for tax purposes.
Since
acquisition on 31 July 2019, turnover of £1.2 billion arising
from the Pfizer consumer healthcare business has been included in
Group turnover. As the business is being integrated into the
Group’s existing activities, it is not practicable to
identify the impact on Group profit since acquisition.
|
|
The fair values of the net assets acquired, including goodwill, are
as follows:
|
|
|
Tesaro
£bn
|
|
Pfizer
consumer
healthcare
£bn
|
|
|
|
|
|
|
Net
assets acquired:
|
|
|
|
|
Intangible
assets
|
3.1
|
|
12.4
|
|
Inventory
|
0.2
|
|
1.0
|
|
Other
net (liabilities)/assets
|
(0.3)
|
|
0.3
|
|
Deferred
tax liabilities
|
(0.3)
|
|
(2.6)
|
|
|
|
|
|
|
|
2.7
|
|
11.1
|
|
Non-controlling
interest
|
|
|
(3.6)
|
|
Goodwill
|
1.2
|
|
3.9
|
|
|
|
|
|
|
Total
consideration
|
3.9
|
|
11.4
|
|
These
amounts are provisional and subject to change.
|
|
Reconciliation of cash flow to movements in net debt
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
Net
debt, as previously reported
|
(21,621)
|
|
(13,178)
|
|
Implementation
of IFRS 16
|
(1,303)
|
|
-
|
|
|
|
|
|
|
Net
debt at beginning of the year, as adjusted
|
(22,924)
|
|
(13,178)
|
|
|
|
|
|
|
Increase
in cash and bank overdrafts
|
826
|
|
479
|
|
Decrease
in liquid investments
|
(1)
|
|
-
|
|
Net
decrease in short-term loans
|
1,065
|
|
1,986
|
|
Increase
in long-term loans
|
(4,794)
|
|
(10,138)
|
|
Repayment
of lease liabilities
|
214
|
|
28
|
|
Debt of
subsidiary undertakings acquired
|
(524)
|
|
-
|
|
Exchange
adjustments
|
1,015
|
|
(776)
|
|
Other
non-cash movements
|
(92)
|
|
(22)
|
|
|
|
|
|
|
Increase
in net debt
|
(2,291)
|
|
(8,443)
|
|
|
|
|
|
|
Net
debt at end of the year
|
(25,215)
|
|
(21,621)
|
|
|
|
|
|
|
Net debt analysis
|
|
|
|
|
2019
£m
|
|
2018
£m
|
|
|
|
|
|
|
|
|
Liquid
investments
|
|
|
79
|
|
84
|
|
Cash
and cash equivalents
|
|
|
4,707
|
|
3,874
|
|
Cash
and cash equivalents reported in assets
held
for sale
|
|
|
507
|
|
485
|
|
Short-term
borrowings
|
|
|
(6,918)
|
|
(5,793)
|
|
Long-term
borrowings
|
|
|
(23,590)
|
|
(20,271)
|
|
|
|
|
|
|
|
|
Net
debt at end of the year
|
|
|
(25,215)
|
|
(21,621)
|
|
|
|
|
|
|
|
|
Free cash flow reconciliation
|
|
|
2019
£m
|
|
2018
£m
|
|
Q4
2019
£m
|
|
|
|
|
|
|
|
|
Net
cash inflow from operating activities
|
8,020
|
|
8,421
|
|
3,453
|
|
Purchase
of property, plant and equipment
|
(1,265)
|
|
(1,344)
|
|
(480)
|
|
Proceeds
from sale of property, plant and equipment
|
95
|
|
168
|
|
9
|
|
Purchase
of intangible assets
|
(898)
|
|
(452)
|
|
(285)
|
|
Proceeds
from disposals of intangible assets
|
404
|
|
256
|
|
316
|
|
Net
finance costs
|
(813)
|
|
(694)
|
|
(340)
|
|
Dividends
from joint ventures and associates
|
7
|
|
39
|
|
7
|
|
Contingent
consideration paid (reported in investing
activities)
|
(113)
|
|
(153)
|
|
(30)
|
|
Distributions
to non-controlling interests
|
(364)
|
|
(570)
|
|
(51)
|
|
Contributions
from non-controlling interests
|
-
|
|
21
|
|
-
|
|
|
|
|
|
|
|
|
Free
cash flow
|
5,073
|
|
5,692
|
|
2,599
|
|
Reporting definitions
|
|
Total and Adjusted results
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 9 and other non-IFRS measures
are defined below.
Free cash flow
Free
cash flow is defined as the net cash inflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests
plus proceeds from the sale of property, plant and equipment and
intangible assets, and dividends received from joint ventures and
associates. It is used by management for planning and reporting
purposes and in discussions with and presentations to investment
analysts and rating agencies. Free cash flow growth is calculated
on a reported basis. A reconciliation of net cash inflow from
operations to free cash flow is set out on page 59.
Free cash flow conversion
Free
cash flow conversion is free cash flow as a percentage of
earnings.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. £%
or AER% represents growth at actual exchange rates.
Pro-forma growth
The
acquisition of the Pfizer consumer healthcare business completed on
31 July 2019 and so GSK’s reported results include five
months of results of the former Pfizer consumer healthcare business
from 1 August 2019.
The
Group has presented pro-forma growth rates at CER for turnover,
Adjusted operating profit and operating profit by business taking
account of this transaction. Pro-forma growth rates at CER for the
quarter are calculated comparing reported results for Q4 2019,
calculated applying the exchange rates used in the comparative
period, with the results for Q4 2018 adjusted to include the
equivalent three months of results of the former Pfizer consumer
healthcare business during Q4 2018, as consolidated (in US$) and
included in Pfizer’s US GAAP results. Similarly, pro-forma
growth rates at CER for 2019 are calculated comparing reported
results for 2019, calculated applying the exchange rates used in
the comparative period, with the results for 2018, adjusted to
include the equivalent five months of results of the former Pfizer
consumer healthcare business, as consolidated (in US$) and included
in Pfizer’s US GAAP results.
|
|
Brand names and partner acknowledgements
Brand
names appearing in italics throughout this document are trademarks
of GSK or associated companies or used under licence by the Group.
Gardasil is a trademark of Merck Sharp & Dohme
Corp.
|
|
Outlook, assumptions and cautionary statements
|
|
2020 guidance
In
2020, GSK expects Adjusted EPS to decline in the range of -1% to
-4% at CER. This guidance excludes any impact in 2020 from any
further material divestments beyond those previously announced and
any potential impact on GSK’s business from the Coronavirus
outbreak.
2016-2020 outlook
In May
2015, GSK announced that it expected Group sales to grow at CER at
a low-to-mid single digits percentage CAGR and Adjusted EPS to grow
at CER at a mid-to-high single digit percentage CAGR for the period
2016-2020. On 3 December 2018, GSK announced that it continued to
expect to deliver on its previously published Group outlooks to
2020, but, following the acquisition of Tesaro, expected Adjusted
EPS growth at CER for the period 2016-2020 to be at the bottom end
of the mid-to-high single digit percentage CAGR range. These
outlooks are based on 2015 exchange rates.
Assumptions related to 2020 guidance and 2016-2020
outlook
In
outlining the expectations for 2020 and the five-year period
2016-2020, the Group has made certain assumptions about the
healthcare sector, the different markets in which the Group
operates and the delivery of revenues and financial benefits from
its current portfolio, pipeline and restructuring
programmes.
For the
Group specifically, over the period to 2020, GSK expects further
declines in sales of Seretide/Advair. The introduction of a
generic alternative to Advair in the US has been factored into
the Group’s assessment of its future performance. The Group
assumes no premature loss of exclusivity for other key products
over the period.
The
assumptions for the Group’s revenue, earnings and dividend
expectations assume no material interruptions to supply of the
Group’s products, no material mergers, acquisitions or
disposals, except for the acquisition of Tesaro, the proposed
divestment of Horlicks and
other Consumer Healthcare products to Unilever and the formation of
a new Consumer Healthcare Joint Venture with Pfizer, all announced
in December 2018, no material litigation or investigation costs for
the Company (save for those that are already recognised or for
which provisions have been made), no share repurchases by the
Company, and no change in the Group’s shareholdings in ViiV
Healthcare. The assumptions also assume no material changes in the
macro-economic and healthcare environment. The 2020 guidance and
2016-2020 outlook have factored in all divestments and product
exits since 2015, including the divestment and exit of more than
130 non-core tail brands (£0.5 billion in annual sales) as
announced on 26 July 2017 and the product divestments planned in
connection with the formation of the Consumer Healthcare Joint
Venture with Pfizer.
The
Group’s expectations assume successful delivery of the
Group’s integration and restructuring plans over the period
2016-2020, including the extension and enhancement to the combined
programme announced on 26 July 2017, the new Major restructuring
plan announced on 25 July 2018, the Consumer Healthcare Joint
Venture integration programme and the new Separation Preparation
programme. They also assume that the proposed divestment of
Horlicks and other Consumer
Healthcare products to Unilever closes in Q1 2020 and that the
integration and investment programmes following the Tesaro
acquisition and the Consumer Healthcare Joint Venture with Pfizer
over this period are delivered successfully. Material costs for
investment in new product launches and R&D have been factored
into the expectations given. Given the potential development
options in the Group’s pipeline, the outlook may be affected
by additional data-driven R&D investment decisions. The
expectations are given on a constant currency basis (2016-2020
outlook at 2015 CER).
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the aspirational targets described
in this report are achievable based on those assumptions. However,
given the longer term nature of these expectations and targets,
they are subject to greater uncertainty, including potential
material impacts if the above assumptions are not realised, and
other material impacts related to foreign exchange fluctuations,
macro-economic activity, changes in regulation, government actions
or intellectual property protection, actions by our competitors,
and other risks inherent to the industries in which we
operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2018. Any forward looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge and information available to the Directors
on the date of this report.
Cautionary statement regarding pro-forma growth rates
The
pro-forma growth rates at CER in this Results Announcement have
been provided to illustrate the position in Q4 2019 relative to the
position in Q4 2018 as if, for the purposes of the Q4 2018 results,
the acquisition of the Pfizer consumer healthcare business had
taken place as at 31 July 2018 and that, accordingly, three months
of results of the former Pfizer consumer healthcare business were
included in Q4 2018. Similarly, pro-forma growth rates have been
provided to illustrate the position for 2019 relative to the
position for 2018 as if, for the purposes of 2018 results, the
acquisition of the Pfizer consumer healthcare business had taken
place as at 31 July 2018 and that, accordingly, five months of
results of the former Pfizer consumer healthcare business were
included in 2018. The results of the former Pfizer consumer
healthcare business included for Q4 2018 and the year-ended 31
December 2018 are as consolidated (in US$) and included in
Pfizer’s US GAAP results. The results for Q4 2019 and the
year-ended 31 December 2019 used to calculate the pro-forma growth
rates are as reported at CER.
The
pro-forma growth rates have been provided for illustrative purposes
only and, by their nature, address a hypothetical situation and
therefore do not represent the Group’s actual growth rates.
The pro-forma growth rates do not purport to represent what the
Group’s results of operations actually would have been if the
Pfizer acquisition had been completed on the date indicated, nor do
they purport to represent the results of operations at any future
date. In addition, the pro-forma growth rates do not reflect the
effect of anticipated synergies and efficiencies or accounting and
reporting differences associated with the acquisition of the Pfizer
consumer healthcare business.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
05, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|